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Abstract
The first chapter of this work describes a novel, enzyme-responsive nanocapsule for the
intracellular delivery of therapeutic nucleic acids and small molecule drugs. The stepwise
assembly of this new construct, referred to as a nucleic acid nanocapsule (NAN), is presented. The
cellular uptake properties of the NAN are investigated through confocal microscopy. Additionally,
the functionalization of the NAN with a therapeutic nucleic acid is described. For these
experiments, the NAN was functionalized with a DNAzyme, a catalytically active DNA molecule
that can specifically bind and cleave a target mRNA sequence. The DNAzyme utilized in these
studies is specific for the mRNA of GATA-3, a protein involved in the inflammatory pathway of
asthma. An initial investigation into the activity of the DNAzyme on the NAN surface is described.
The second chapter expands on the characterization of the DNAzyme-NAN, including an
investigation into the stability of the chemically unmodified nucleic acid presented on the NAN
surface and the effect of the surfactant on the endosomal escape of the DNAzyme. Additionally,
the cellular uptake properties of the DNAzyme-NAN are investigated through confocal
microscopy, and the catalytic activity of the DNAzyme on the NAN surface is investigated through
a series of mRNA and protein knockdown studies. In the third chapter, in vitro studies of the
DNAzyme-NANs are expanded to primary human immune cells, showing the versatility of the
NAN construct. DNAzyme-NANs were also tested in in vivo studies in an associated allergic
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airway disease mouse model. Chapter four investigates the ability of the NAN to co-deliver a
therapeutic oligonucleotide with a small molecule drug. The encapsulation of a novel gold(III)
metallodrug in the hydrophobic core of the NAN, and the functionalization of the NAN surface
with siRNA targeting Bcl-2, a gene involved in cellular apoptosis, are described. The enhanced
cytotoxicity of the drug when co-delivered with the therapeutic nucleic acid using the NAN
platform is presented. The last chapter describes the functionalization of NANs with an aptamer
targeting Annexin A2, a cell-surface protein, for targeted delivery and cell-specific gene
knockdown. In closing, future outlook and potential applications of the NAN platform are
discussed.
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Introduction
Nucleic acid-based therapeutics have become increasingly popular in the treatment of various
diseases, as they have been shown to be capable of highly specific gene silencing with limited
immune response.1,2,3 Therapeutic nucleic acids can include aptamers, antisense oligonucleotides,
siRNA, and catalytic nucleic acids.

Antisense oligonucleotides (ASOs) are short, single stranded DNA molecules that bind
complementary mRNA sequences, resulting in the regulation of protein expression. The binding
of an ASO to target mRNA leads to the recruitment of RNase H, an endonuclease that specifically
cleaves the RNA of a DNA/RNA duplex.4 RNase H-mediated cleavage of mRNA results in the
reduction of protein expression. However, ASOs can also regulate protein expression through the
inhibition of ribosomal activity or the destabilization of pre-mRNA in the nucleus.5,6 Alternatively,
small interfering RNA, or siRNA, consists of a short (19-25 base pair) RNA duplex. The antisense
strand of the duplex is complementary to a target mRNA sequence, leading to cleavage of mRNA
via RNA interference, a protein-based mechanism which results in gene silencing.

Another class of oligonucleotides that can form antisense interactions with target mRNA are in the
form of aptamers. Aptamers are single-stranded oligonucleotides that have been evolved in vitro
to bind specific targets with high affinity, with Kd values typically ranging from 10 pM to 10 nM.7
The single-stranded DNA or RNA motif that comprises an aptamer typically folds into a defined
structure, capable of forming specific interactions with a target molecule. Aptamers are isolated
via an in vitro selection, also known as SELEX (systematic evolution of ligands by exponential
enrichment).8,9 In recent years, significant research interest has been on the potential of aptamers
1

for sensing, diagnostics, and therapeutics.10 While they can bind a wide range of targets, aptamers
are commonly selected to bind various protein and cell surface targets.11,12,13

Figure 0.1. Targets of therapeutic nucleic acids.
Catalytic nucleic acids (DNAzymes and ribozymes), antisense oligonucleotides
(ASOs), and siRNA achieve gene regulation by targeting and disrupting mRNA,
resulting in the loss of protein translation. Alternatively, aptamers have evolved the
ability to bind a wide range of targets, with proteins being the most common.

In the 1980s, it was found that the in addition to antisense interactions, some nucleic acids have
also evolved catalytic function.49 Catalytic nucleic acids are oligonucleotides that have evolved
the ability to directly cleave a target mRNA sequence without the aid of proteins. Catalytic nucleic
acids range from naturally occurring ribozymes, to a host of synthetic DNAzymes and ribozymes
that are also selected via SELEX methods. In general, catalytic nucleic acids show significant
potential as therapeutics due to their catalytic capacity and rapid turnover.14,15 The binding affinity
and cleavage capabilities of a DNAzyme make it an efficient antisense oligonucleotide (ASO) for
the recognition of an mRNA target. The first RNA-cleaving DNAzyme was reported in 1994 by
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Breaker and Joyce.16 Since then, DNAzymes have been selected to have a wide range of activity,
including RNA ligation,17 DNA ligation,18 and DNA cleavage.19

However, the intracellular delivery of therapeutic oligonucleotides presents a major challenge, due
to their size and charge. Cationic lipid transfection agents are typically used to facilitate the
transport of nucleic acids across the lipid bilayer of a cell.20 In general, these lipids consist of a
positively charged head group that interacts with the negatively charged phosphate backbone of
the nucleic acids and a hydrophobic tail region that consists of 1-2 hydrocarbon chains (Figure
0.2).

Figure 0.2. Cationic transfection agent structure.
Chemical structure of 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP), a
commonly used cationic transfection agent.

Although they result in effective in vitro delivery of nucleic acids, these transfection agents have
been shown to be toxic at higher concentrations required for in vivo delivery of therapeutic nucleic
acids, as the cationic lipid can destabilize the plasma membrane of the cell.21,22 Cationic lipids can
also cause significant changes in cell morphology, including cell shrinking.23 Additionally,
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cationic lipids have been shown to inhibit the activity of various proteins, including protein kinase
C.24 Thus, there is an increasing need for nontoxic delivery vehicles for therapeutic nucleic acids.

Current delivery methods include lipid nanoparticles,25–28 polymeric nanoparticles,29,30
conjugation of cell penetrating peptides (CPPs),31,32 antibodies,33,34 and exosomes.35,36 In
particular, the spherical nucleic acid (SNA) construct developed in 1996 by Mirkin and coworkers
has been shown to be a promising nanoparticle-based delivery system for therapeutic
oligonucleotides.37 However, a majority of nucleic acid delivery systems result in internalization
via endocytosis.20 There are three main pathways of endocytosis: clathrin-mediated endocytosis,
caveolae-mediated endocytosis, and clathrin- and caveolin-independent endocytosis.38 Clathrinmediated endocytosis results in cellular uptake of a wide range of materials via clathrin-coated
vesicles, or pits.39,40 Alternatively, caveolae-mediated endocytosis involves the interaction of
caveolae, which are highly uniform invaginations of the plasma membrane that are enriched in
cholesterol and sphinoglipids,41 with various ligands, resulting in internalization.42 Additionally,
several clathrin- and caveolin-independent pathways have been reported.43

Internalization via endocytosis results in cargo trapped in membrane-bound vesicles known as
endosomes. Endosomes undergo various sorting, recycling, and maturation processes, in which
the cargo is either returned back to the cell surface or, more commonly, targeted for degradation
via lysosomes.44 As endosomes mature into lysosomes, the pH drops, from a pH of about 6.8 in
early endosomes, to a pH in the range of 5.0-6.2 in late endosomes, and finally to a pH of around
4.5 in lysosomes.45 Additionally, lysosomes contain a large number of acid hydrolase enzymes
that degrade the cargo.46

4

Figure 0.3. Cellular uptake via endocytosis.
Cellular uptake of therapeutic nucleic acid delivery vehicles via
endocytosis. For successful therapeutic efficacy, the nucleic acid
cargo must undergo endosomal escape to engage the mRNA target
in the cytosol of the cell.

As the targets of many nucleic acid therapeutics are in the cytosol of the cell, endosomal escape of
the oligonucleotide is critical. There are a number of mechanisms for effective endosomal escape,
including cell penetrating peptides, pH buffering effects, destabilization of the endosomal
membrane, and pore formation.20,47,48 Thus, the most effective delivery vehicles are those that can
facilitate endosomal escape of the nucleic acid. Although they are readily endocytosed via
scavenger receptors, the gold nanoparticle core of the SNAs cannot pass through a lipid membrane
and thus much of them remain trapped in the endosomal vesicles.
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The work presented herein describes the assembly of a new, modular enzyme-responsive nucleic
acid nanocapsule (NAN) that is specifically designed to address the challenges of intracellular
nucleic acid delivery. Its design allows for both the encapsulation of a small-molecule drug and
the functionalization of nucleic acids at the surface, enabling combinations of therapeutic
molecules to be delivered into cells. The first chapter describes the initial design and
characterization of the NAN, including an investigation into the NANs ability to undergo cellular
uptake through endocytosis. Following chapters focus on the NANs potential as a delivery vehicle
for small molecule cargo, including fluorescent dyes and anti-cancer drugs, in addition to
therapeutic oligonucleotides (DNAzymes, siRNA, aptamers).
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Chapter 1
Design of an enzyme-responsive nucleic acid nanocapsule (NAN) for drug delivery
Adapted from: Awino, J. K.; Gudipati, S. G.; Hartmann, A. K.; Santiana, J. J.; Cairns-Gibson, D.
F.; Gomez, N.; Rouge, J. L. Nucleic Acid Nanocapsules for Enzyme-Triggered Drug Release. J.
Am. Chem. Soc. 2017, 139, 6278-6281.
Introduction
In recent years, nucleic acids have shown great promise in the treatment of various diseases. There
are currently several therapeutic oligonucleotides in clinical development, and multiple have been
approved by the FDA, including Macugen, an RNA aptamer approved in 2004 for the treatment
of age-related macular degeneration (AMD),1,2 Spinraza, an antisense oligonucleotide (ASO)
approved in 2016 for the treatment of spinal muscular atrophy (SMA),3,4 and most recently
Onpattro, which is an siRNA-based drug that gained FDA approval in 2018 for the treatment of
hereditary transthyretin-mediated amyloidosis.5,6

Despite the vast therapeutic potential of nucleic acids, their chemical instability and challenging
delivery has limited their widespread application.7,8 Nucleic acids are biopolymers comprised of
individual nucleotide monomers, which consist of a nitrogenous base, a phosphate group, and a
sugar (ribose in RNA, deoxyribose in DNA) (Figure 1.1). The presence of the 2’-hydroxyl group
makes RNA particularly susceptible to the hydrolysis of the phosphodiester bond. The
deprotonation of the 2’-OH group leads to the nucleophilic attack of the phosphorus, resulting in
cleavage of the backbone. As DNA lacks the 2’-OH group, spontaneous hydrolysis of the
backbone is incredibly slow (computer models predict that at physiological conditions, the halflife is approximately 30 million years).9 However, hydrolysis of the phosphate backbone present
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in nucleic acids can be catalyzed by various metal and lanthanide ions.9,10 Alternatively, nucleic
acids can undergo enzymatic degradation. Nucleases are enzymes that cleave the phosphodiester
backbone of nucleic acids, and include deoxyribonucleases (DNases) and ribonucleases (RNases).
Numerous catalytic nucleic acids (ribozymes and DNAzymes) can also result in phosphate
backbone cleavage of a target nucleic acid.

Figure 1.1. Nucleotide monomers of DNA and RNA.

As nucleic acids are inherently unstable molecules, they typically require heavy chemical
modifications to increase their lifetime in cellular environments. Common modifications include
phosphorothioate modifications to the backbone, modifications to the 2’position of the nucleoside,
or locked nucleic acids (LNAs) (Figure 1.2).11,12 Phosphorothioate backbone modifications
involve the replacement of a non-bridging oxygen with sulfur in the phosphate backbone of the
nucleic acid. This modification improves the stability of the nucleic acid against nucleases and
promotes binding of serum proteins, extending the half-life and increasing bioavailability.13,14,15
However, a high degree of phosphorothioate modifications has been shown to have cytotoxic
effects.16 Modifications to the 2’-hydroxyl of the ribose include 2’-O-methyl and 2’-fluoro.17
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Alternatively, locked nucleic acids (LNAs) involve bridging of the sugar ring via a methylene
linkage between the 2’ and 4’ positions of the ribose.12 While both of these modifications
contribute to enhanced thermal and protection against nuclease degradation, they do not allow for
RNase H activity.12,18 Thus, to allow for RNase H-mediated cleavage of target RNA, the modified
sequence must contain several consecutive DNA bases between regions of modified bases, referred
to as a gapmer.19 Although widely used, chemical modifications can also alter the folding
properties of nucleic acids, which can affect oligonucleotides that rely on structure for therapeutic
activity.20,21 Specifically, chemical modifications to DNAzymes have been shown to decrease
specificity and cleavage activity, due to changes in secondary structure.22

Figure 1.2. Common modifications of DNA and RNA.
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The intracellular delivery of therapeutic nucleic acids also presents a major challenge. The large,
negatively charged oligonucleotides cannot cross the positively charged lipid bilayer of the cell.7,23
Typically, nucleic acids are delivered into cells via transfection. While there are a wide range of
transfection agents, many common and commercially available formulations consist of cationic
lipids that form complexes with the negatively charged nucleic acids. In general, these newly
formed liposomal vehicles will fuse with the lipid membrane of the cell, releasing the nucleic acid
cargo into the cytosol.24 However, these common in vitro transfection agents have been shown to
exhibit toxicity at the higher concentrations required for in vivo applications.25

In recent years, significant progress has been made to develop effective and nontoxic delivery
methods for therapeutic nucleic acids.26 SNAs, as introduced earlier, consist of thiolated DNA
attached to a gold nanoparticle surface.27 The dense coating of nucleic acids on the nanoparticle
surface has been shown to offer significant advantages over other traditional delivery methods.
These structures are considered to be “self-transfecting”, as they undergo active uptake that is
facilitated by interactions with membrane bound scavenger receptors.23,28 More specifically, SNAs
are reported to undergo lipid-raft dependent caveolae-mediated endocytosis via the targeting of
class A scavenger receptors.29 The SNA construct has also been shown to increase the half-life of
unmodified nucleic acids presented on the surface of the nanoparticle, as the dense coating allows
for the protection of the ligands against degradation from nucleases.30 This property is especially
beneficial as nucleic acids are inherently unstable molecules, degrading in cells on the order of
minutes,31 and typically require heavy chemical modifications, which can result in structural
changes and decreased efficacy. Additionally, SNAs exhibit low toxicity and immunogenicity.32
The gold nanoparticle-based SNA structure has shown success in the delivery of various
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therapeutic nucleic acids, including antisense oligonucleotides,33 siRNA,34,35 and catalytic nucleic
acids.36,37,38 While the gold nanoparticle core of the SNA construct has been the most studied, other
inorganic cores have also been investigated, including silica39 and iron oxide.40

Although SNAs have been shown to effectively deliver various therapeutic nucleic acid ligands,
they are limited by the inorganic core of the construct. The nanoparticle core is not fully
biodegradable, and only serves as a scaffold for the nucleic acid ligands. After endocytosis, the
core cannot readily pass through the endosomal bilayer. Thus, many of the particles may remain
trapped in cellular endosomes. As the target of many therapeutic nucleic acids is in the cytosol of
the cell, endosomal escape is critical.

Thus, the focus of this chapter was to design a novel nucleic acid delivery vehicle that took
advantage of properties offered by the SNA structure, including active uptake mechanisms and
enhanced stability of the chemically unmodified nucleic acid ligands on the surface, but one which
offered biodegradability. A nanocapsule that could degrade intracellularly, in the presence of
specific biochemical stimuli, could allow for enhanced efficacy of the therapeutic nucleic acid
ligand. In this chapter, a novel construct developed by our research group, referred to as a nucleic
acid nanocapsule (NAN), is introduced.

The NAN construct is built via an initial self-assembly of surfactant molecules into a micelle,
followed by chemical crosslinking of the head groups of the surfactant (Figure 1.3). The
crosslinking of the nanocapsule is important as it offers additional stability over traditional micelle
structures and serves as a recognition site for enzyme-mediated cleavage, allowing for
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biochemically controlled degradation. Thiolated DNA is attached to the surface of the crosslinked
micelle, resulting in a dense coating of therapeutic oligonucleotides. Additionally, the micelle core
allows for the encapsulation of hydrophobic cargo, that can be co-delivered and released
intracellularly upon NAN degradation.

Figure 1.3. Nucleic acid nanocapsule (NAN) platform.

Synthesis and Characterization of SCMs and NANs. Nucleic acid nanocapsules (NANs) are
prepared via a stepwise assembly starting with individual surfactant precursors (Scheme 1.1). The
surfactant molecules are a unique building block developed by Awino et al.41 The design of the
surfactants was inspired by surfactant molecules developed by Zhao and coworkers,42,43 and
adapted for biological studies. 3.8 mg of surfactant (0.01 mmol) is first dissolved in 1 mL water,
to form a 10 mM solution. The surfactant structure consists of a C12 chain and a trialkyl head
group. In water, the surfactants self-assemble into a micelle, which is then stabilized through
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crosslinking of the surfactant head groups. The crosslinker is functionalized with two azide groups
on either end that react with the alkyne head groups of the surfactant through copper(I)-catalyzed
alkyne-azide cycloaddition (CuAAC) click chemistry. This crosslinking step is important as it both
provides stability to the micelle structure and allows for enzymatically triggered degradation of
the micelle. Initially, two different chemical crosslinkers were designed: a diazido PEG and a
diazido ester crosslinker (Figure 1.4).

Scheme 1.1. Stepwise assembly of SCMs.
Tri-alkyl modified surfactant is dissolved in water, forming micelles. The micelle is then
crosslinked with a diazido PEG or diazido ester ester crosslinker via Cu(I) catalyzed alkyne-azide
cycloaddition click chemistry.

Figure 1.4. Crosslinkers used in SCM synthesis.
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Figure 1.5. Copper(I) catalyzed formation of a triazole linkage.

The ester crosslinker was designed as an enzyme recognition site, allowing for the degradation of
the NAN by esterases, which are hydrolase enzymes that catalyze the cleavage of ester groups via
hydrolysis. Recent studies have shown that esterase-responsive degradation sites are effective
targets for the release of therapeutics.44 Additionally, the ester-based crosslinker was chosen due
to the increased concentration of esterases present in cellular endosomes,45,46 allowing for the
intracellular degradation of the nanocapsule. Alternatively, the PEG crosslinker was used as a nondegradable control in various studies.

After successful crosslinking, the surface crosslinked micelles (SCMs) are purified via size
exclusion chromatography using a Sephadex G-25 NAP-10 column. The fractions containing
nanoparticles are then characterized through dynamic light scattering (DLS) and zeta potential
measurements, to measure the average size and surface charge, respectively (Figure 1.6). The ester
crosslinked SCMs exhibited a size of approximately 20 nm and a surface charge of roughly +50
mV, due to the presence of tertiary amines in the head group of the surfactant.
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Figure 1.6. Size and charge of ester-crosslinked SCMs.
Full width at half maximum (FWHM) of the size distribution was
calculated to be 12.5.

Scheme 1.2. Formation of NAN.
The functionalization of the SCM surface with thiolated DNA via a UVmediated thiol-yne reaction forms the NAN structure.

To form the nucleic acid nanocapsules (NANs), the remaining alkyne of each surfactant head
group is then further functionalized with thiolated DNA via a UV-mediated thiol-yne reaction
(Scheme 1.2). The stoichiometric ratio of alkyne: DNA in the reaction is 1: 2, as the alkyne can
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form covalent bonds with two separate thiolated DNA molecules. The NANs are purified via a
Sephadex G-25 NAP-10 column and characterized through DLS and zeta potential measurements.
After successful attachment of DNA on the surface, ester crosslinked NANs exhibited an average
size of 29.3 ± 2.3 nm and a surface charge of -40.4 ± 2.9 mV, due to the negatively charged
phosphate backbone of the nucleic acids on the surface (Figure 1.7).

Figure 1.7. Size and charge of ester-crosslinked NANs.
Full width at half maximum of the size distribution of the NANS was calculated to be 14.7.

The successful preparation of SCMs and NANs was also visualized using agarose gel
electrophoresis. Rhodamine B was encapsulated into the hydrophobic core of the micelle, allowing
for the visualization of the SCMs and NANs. To encapsulate the dye, rhodamine B was first
dissolved in DMSO to a final concentration of 13 mg/mL. 5 µL of the dye (0.00025 mmol) was
then added to the surfactant dissolved in water and sonicated for 5-10 minutes. The dye-loaded
micelles were then moved forward for crosslinking. After purification, SCMs and NANs
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containing rhodamine B were run in a 1% agarose gel at 120 V for 30 minutes, and the gel was
scanned at 532 nm. The agarose gel in Figure 1.8 shows the difference between the positively
charged SCMs and the negatively charged NANs.

Figure 1.8. 1% agarose gel of rhodamine B loaded SCMs and NANs.
The charge of the SCMs is positive due to the tertiary amine of the
surfactant head group, while NANs carry a negative charge due to the
DNA on the surface. As the gel is unstained, bands represent encapsulated
dye.

Investigation of active cellular uptake mechanism of NANs. Once fully functionalized and
characterized, it became of interest to investigate the cellular uptake of the NANs. Due to the SNAlike structure of the NANs (the spherical shape with a dense coating of nucleic acids on the
surface), it was hypothesized that the NANs would undergo endocytosis without the need for
common transfection agents. Cellular uptake of the NANs was investigated through confocal
microscopy. For these studies, SCMs were synthesized in the presence of rhodamine B and
crosslinked with a diazido PEG crosslinker. The non-degradable crosslinker was chosen so that
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the NAN structure would remain intact in the cellular environment, allowing for visualization of
the entire NAN construct. HeLa cells were treated with 1 µM rhodamine B NANs in OptiMEM
for 4 hours at 37 °C. Prior to imaging, cells were stained with Hoechst 33342 and Lysotracker
Deep Red. Images were taken with a Leica SP8 confocal microscope. After incubation, the
confocal images showed the NANs (green signal) co-localized in the endosomes (red signal),
showing that the NANs enter the cells via endocytosis (Figure 1.9).

Figure 1.9. Confocal microscopy images.
Confocal images of HeLa cells treated with 1 µM rhodamine B NANs. A) rhodamine B
(NANs), B) Lysotracker deep red (endosomes), C) overlay of NAN and endosomes with
DAPI (nucleus), D) brightfield image overlay. All scale bars are 20 µm.41

Functionalization of NAN with therapeutic nucleic acid. After confirming the active uptake of
the NANs by HeLa cells, it was of interest to investigate whether the NAN construct could be used
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in the delivery of a therapeutic nucleic acid. For these studies, a GATA-3 targeting DNAzyme was
used, that has been shown to rapidly cleave a target mRNA sequence.47,48 The DNAzyme was
assembled onto the surface of the NAN using a recently developed enzymatic ligation approach
(Scheme 1.3).49

Scheme 1.3. Ligation of DNAzyme to NAN surface.
DNAzyme is first hybridized to anchor present on the NAN surface by a bridge. The ligation between
the anchor and DNAzyme is then achieved using T4 DNA ligase.
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NANs functionalized with thiolated AH anchor were added to DNAzyme and bridge (sequences
in Table 1.1) in a 1.3: 10: 20 ratio (NAN: DNAzyme: bridge). After the ligation, DNAzymefunctionalized NANs were purified via a Sephadex G-25 NAP-10 column and characterized
through DLS measurements (Figure 1.10). The successful ligation showed a shift in the average
size from 21.3 ± 4.1 nm to 64.0 ± 10.1 nm for the NAN and DNAzyme-NAN, respectively.

Table 1.1. DNA and RNA sequences.
Blue represents monophosphorylation to allow for recognition by T4 DNA ligase, red represents
mutations made in DNAzyme sequence.

Figure 1.10. DLS characterization of DNAzyme-NANs.
The shift in size shows the successful ligation of the DNAzyme to the surface of the NAN.
Full width at half maximum was calculated to be 14.7 for the NANs, and 24.3 for the
DNAzyme-NANs.
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Investigation of DNAzyme activity on NAN surface. As DNAzymes rely on the correct folding
for therapeutic activity, it was important to investigate the in vitro cleavage ability of the
DNAzyme after the immobilization on the NAN surface. For these assays, a truncated version of
the full length GATA-3 mRNA sequence was utilized (Table 1.1). Importantly, this truncated
sequence corresponds to the specific binding site for the DNAzyme on the full-length mRNA. The
5’ end of the mRNA truncate was labeled with a terminal Cy3 dye, allowing for the visualization
of the full length vs. cleaved sequence. 0.5 µM mRNA truncate was incubated with either free
DNAzyme or 5 µM DNAzyme-NANs at 37 °C for 4 hours, both with and without appropriate salts
(10 mM MgCl2, 100 mM NaCl). The resulting products were then run on an 8% denaturing
polyacrylamide gel (Figure 1.11).

Figure 1.11. DNAzyme-NAN activity assay.
DNAzyme-NANs incubated with a Cy3-labeled mRNA truncate show comparable
cleavage to the free DNAzyme control. Additionally, mutated DNAzyme-NANs
do not show any cleavage of the truncate.41
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Compared to the positive control (free DNAzyme), the DNAzyme-NANs showed similar
cleavage, as seen by the cleavage product in the gel. As expected, there is no cleavage visualized
in the absence of salts, as the salts are necessary for the appropriate fold and activity of the
DNAzyme. It was also of interest to investigate the specificity of the DNAzyme. Four mutations
were made in the flanking region of the DNAzyme (Table 1.1). These mutations are important
because the DNAzyme has lost specificity for the target mRNA sequence, but still retains all
catalytic activity. As seen in the gel in Figure 1.11, the mutated DNAzyme on the NAN surface
did not show any cleavage of the target mRNA. These results indicate that the DNAzyme retains
its catalytic activity even after immobilization on the NAN surface. Moreover, the DNAzyme is
incredibly specific for its target, and the close proximity of the DNAzymes on the surface do not
result in any non-specific cleavage.

Summary
This chapter described the design and synthesis of a nanoparticle that can serve as an effective
delivery vehicle for therapeutic nucleic acids. Additionally, the core of the micelle can be utilized
in the delivery of small, hydrophobic cargo as shown by the use of a dye as cargo. The NAN is
built via a stepwise assembly and can be easily modified with therapeutic nucleic acids. Moreover,
the degradation of the NAN can be triggered intracellularly in the presence of specific enzymes.

While the enzyme-mediated degradation of the NAN was exciting, it was also of interest to tune
the specificity of the crosslinker to respond to elevated enzyme expression in diseased states, as
this specificity can reduce unwanted off-target effects. Additionally, although the DNAzyme-NAN
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showed effective cleavage of the truncated mRNA sequence, a question that remained was whether
the same cleavage could be seen intracellularly.
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Chapter 2
Achieving endosomal escape: a study of GATA-3 mRNA cleavage by DNAzyme-surfactant
conjugates
Adapted from: Hartmann, A. K.; Cairns-Gibson, D. F.; Santiana, J. J.; Tolentino, M. Q.; Barber,
H. M.; Rouge, J. L. Enzymatically Ligated DNA-surfactants: Unmasking Hydrophobically
Modified DNA for Intracellular Gene Regulation. ChemBioChem 2018, 19, 1734-1739.

Introduction
Significant progress has been made on the design of effective delivery vehicles for therapeutic
nucleic acids. However, many undergo cellular uptake via endocytosis, resulting in cargo trapped
in cellular endosomes. As the target of many therapeutic nucleic acids is in the cytosol of the cell,
endosomal escape is important for achieving activity of the delivered oligonucleotides.

There are numerous mechanisms for endosomal escape, and the most effective nucleic acid
delivery vehicles are those that can aid in the release of the oligonucleotide into the cytosol.
Membrane destabilization by cationic peptides or lipids can lead to pore formation, resulting in
gradual leakage of endosomal contents.1 In addition, fusion of lipid-based delivery vehicles with
the endosomal membrane results in cargo released into the cytosol.2 Endosomal escape can also
be achieved by taking advantage of the pH changes during endosomal maturation. Early
endosomes have a pH of approximately 6.8, which drops to 5.0-6.2 in late endosomes and finally
to 4.5 in lysosomes.3 Peptides that undergo structural changes in response to acidic pH can be
utilized to disrupt endosomal membranes.4 In addition, various weak bases can be utilized as
“proton sponges”, which are used to buffer the acidification of the endosome, resulting in rupture
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of the endosome due to osmotic pressure.5,6 Although they show promising mechanisms of
endosomal escape, many delivery vehicles do not achieve significant release of cargo into the
cytosol.7,8,9 Thus, though many delivery vehicles show enhanced cellular uptake, effective
endosomal escape remains a major hurdle in the widespread use of therapeutic nucleic acids.

The nucleic acid nanocapsule (NAN) construct introduced in Chapter 1 was shown to undergo
cellular uptake via endocytosis. Additionally, the crosslinker present in the NAN platform allows
for enzyme-mediated degradation. As esterases are present in high concentrations in cellular
endosomes,10,11 the NAN should undergo esterase-mediated cleavage while trapped in the
endosome, resulting in the release of individual DNA-surfactant conjugates. It is hypothesized that
the surfactant tail will aid in the endosomal escape of the nucleic acid, as the hydrophobic region
can aid in the disruption of the endosomal membrane.12,13 In this chapter, the concept of endosomal
escape of the DNA-surfactant conjugates is explored through various in vitro studies. The surface
of the NAN is functionalized with a DNAzyme specific for the mRNA of GATA-3. As the mRNA
target is in the cytosol of the cell, the DNAzyme must effectively escape the endosome to achieve
mRNA cleavage and GATA-3 protein knockdown.

GATA-3 is a transcription factor that is a key regulator of the differentiation of naïve T cells into
T helper type 2 (Th2) cells in the inflammation response of asthma. Due to the critical role that
GATA-3 plays in inflammation, it shows promise as a target for gene silencing therapies for
asthma and related inflammatory diseases.

30

Asthma is a common chronic airway disease that is increasing in prevalence in the United States.14
According to the Center for Disease Control (CDC), asthma affects more that 25 million
Americans, which includes 6.2 million children.15 Moreover, the CDC estimates that the medical
cost of asthma is over $50 billion annually. Many patients with asthma suffer from mucus
hypersecretion, airway inflammation and remodeling, difficulty breathing, and wheezing.
Traditional treatments for asthma can be divided into two categories: short-term control and longterm control. Short-term treatments are often labeled as “quick-relief”, consisting of inhaled
bronchodilators to quickly open airways. One common quick-relief treatment is inhaled short-term
beta agonists, which achieve relaxation of the airways via activation of b2 adrenoceptors located
on the cells of the airway smooth muscle.16 Long-term medications include inhaled corticosteroids,
leukotriene modifiers, and long-acting beta agonists. Of these, inhaled corticosteroids are the most
commonly used, as they effectively suppress airway inflammation.17 Alternatively, leukotriene
modifiers block the action of leukotrienes, which are fatty acids that have been shown to enhance
mucus secretion and increase bronchial hyperresponsiveness.18 Long-acting beta agonists work to
relax the muscles of the airway over time, making it easier to breathe.

However, despite their widespread use, these traditional small molecule drug therapies for asthma
have various drawbacks. Studies have shown that there are higher risks associated with giving the
small molecule drugs to children,19 and there are also various concerns over the safety of longterm use of b agonists.20 Additionally, approximately 5-10% of patients with asthma do not
respond to the traditional corticosteroid treatment.21 These patients typically require higher
dosages of the medications or the addition of secondary treatment options.
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To overcome the challenges presented by the traditional drug treatments, various antibody-based
therapies have been developed, targeting key cytokines including IL-422 and IL-5.23 However,
many antibody therapies have shown limited efficacy,24,25 and often have numerous adverse side
effects.26 Additionally, antibodies are produced in vivo, which is a slow and expensive process,
and can lead to variations between batches.27 Thus, there is a growing need for safe and effective
therapeutics for the treatment of asthma.

Catalytic nucleic acids have become increasingly popular in the treatment of various diseases, as
they are capable of highly specific gene regulation with limited immune response. These DNA or
RNA molecules (DNAzymes or ribozymes, respectively), are often selected via SELEX methods
to achieve highly efficient, sequence-specific cleavage of the phosphodiester backbone of a target
mRNA sequence, resulting in intracellular gene knockdown.28,29 Herein, it was of interest to utilize
the NAN platform described in Chapter 1 for the intracellular delivery of a GATA-3 specific
DNAzyme, hgd40 (Figure 2.1), that was isolated via an in vitro selection.30,31
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Figure 2.1. GATA-3 specific DNAzyme hgd40.
Hgd40 is in the 10-23 family of DNAzymes, which consist of a 15-nucleotide catalytic loop and
two short (7-8 nucleotide) flanking regions that specifically bind the target mRNA sequence.32
Hgd40 specifically binds the mRNA for GATA-3, resulting in mRNA cleavage and loss of GATA3 protein.

The selection by Krug and co-workers resulted in 70 DNAzymes that were tested for GATA-3
mRNA cleavage in in vitro assays. Of these, a few DNAzyme sequences showed promising
cleavage of target mRNA.30 One of the sequences, named hgd40, was further modified with a 3’inverted thymidine, which has been shown to enhance stability of nucleic acids by increasing
nuclease resistance,33 and utilized in additional studies. In in vivo assays, hgd40 exhibited low
toxicity after inhalation.34 Additionally, hgd40 showed favorable biodistribution and
pharmacokinetic properties in animal models.35 Based on the promising therapeutic potential
shown in initial in vivo studies, hgd40 became the active ingredient in SB010, a drug developed
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by Sterna Biologicals. Human patients that received SB010 in clinical trials showed promising
results, including improved lung function and low off-target effects.36 However, the long-term
safety and efficacy of SB010 have not been determined.

In this chapter, the NAN construct was utilized for the intracellular delivery of chemically
unmodified hgd40 DNAzyme for GATA-3 gene regulation. The stability of the chemically
unmodified DNAzyme on the surface of the NAN was investigated through the incubation with
nucleases mimicking the cellular environment. It was also of interest to study the enzyme-mediated
degradation of an ester-responsive NAN, specifically how the surfactant tail affected the
endosomal escape of the DNAzyme. The cellular uptake and intracellular cleavage activity of the
DNAzyme was studied. In MCF-7 cells, confocal microscopy showed the presence of a dyelabeled DNAzyme in the cell, and quantitative polymerase chain reaction (qPCR) showed the
effective cleavage of GATA-3 mRNA.

Preparation of DNAzyme-functionalized NANs. To make the surface crosslinked micelles
(SCMs), 1.9 mg of tri-alkyl modified surfactant (0.005 mmol) was first self-assembled into
micelles in water. Crosslinking of the micelles was done via a copper-catalyzed click reaction
between the azide groups of the crosslinker and the alkyne groups presented on the micelle surface
for the ester-crosslinked SCMs (Scheme 2.1).
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Scheme 2.1. Stepwise assembly of DNAzyme-NANs.
The assembly of DNAzyme-NANs beginning with individual surfactant molecules. After self-assembly
into micelles in water, the micelles are crosslinked with a diazido ester crosslinker via Cu(I) catalyzed click
chemistry, forming SCMs. The SCMs are further functionalized with thiolated DNA via a UV-mediated
thiol-yne reaction to form NANs. Monophosphorylated GATA-3 DNAzyme is then enzymatically ligated
to the NAN surface to form DNAzyme-NANs.

After self-assembly and crosslinking, SCMs were purified via a Sephadex G-25 NAP-10 column,
and the fractions were analyzed by dynamic light scattering (DLS) and zeta potential
measurements. The ester-crosslinked SCMs exhibited a size of approximately 20 nm and had an
average surface charge around +50 mV, as shown in (Figure 2.2). The positive charge is due to
the tertiary amine of the surfactant that is presented on the surface of the SCM.
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Figure 2.2. DLS and zeta potential measurements of SCMs.
Full width at half maximum for the size distribution was calculated to be 12.5.

Table 2.1. DNA and RNA sequences.
Blue represents monophosphorylation for T4 DNA ligase recognition, red represents mutations.
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To form the nucleic acid nanocapsules (NANs), thiolated DNA was added to the remaining alkyne
group on the SCM surface via a UV-mediated thiol-yne reaction in a 1: 2 NAN: DNA ratio
(Scheme 2.1). After successful addition of thiolated DNA on the surface, the NANs were roughly
29 nm and -40 mV (Figure 2.3). The shift in charge is due to the addition of negatively charged
nucleic acids on the surface of the nanocapsule.

Figure 2.3. DLS and zeta potential measurements of NANs.
Full width at half maximum for the size distribution was calculated to be 14.7.

NANs were further functionalized with a chemically unmodified GATA-3 DNAzyme through
enzymatic ligation (Scheme 2.1). After the ligation, DNAzyme-NANs were purified using a
Sephadex G-25 NAP-10 column, and the fractions were characterized via DLS measurements. For
the ester-crosslinked DNAzyme-NANs, the average size shifted to approximately 64 nm,
indicating the successful addition of the 33-base pair DNAzyme to the surface (Figure 2.5). The
addition of the mutated DNAzyme to the surface of the ester-crosslinked NAN resulted in a size
of approximately 74 nm (Figure 2.5).
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Figure 2.4. Calculation of expected DNAzyme-NAN size.
Schematic depicting the calculation of expected size of DNAzyme-NANs,
corresponding to the addition of anchor and DNAzyme to the surface of
SCMs. The average size of DNAzyme-NANs is calculated to be
approximately 56.5 nm, which corresponds well to observed size by DLS
measurements.

Figure 2.5. DLS measurements of NANs after successful ligation of
DNAzyme or mutated DNAzyme.
Full width at half maximum for the size distribution was calculated to be 24.3
for the DNAzyme-NANs and 32.5 for the mutated DNAzyme-NANs.
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To determine the efficiency of the NAN synthesis and the ligation of DNAzymes to the surface, a
fluorescence-based assay was developed to quantify the number of DNAzymes per NAN. For
these studies, a TYE563-labeled DNAzyme was ligated to the surface of ester-crosslinked NANs.
The NANs were then treated with an equivalent volume of 8M urea at 70 °C and purified via size
exclusion chromatography to remove any unligated DNAzymes. Fluorometric measurements were
taken of the column fractions containing DNAzyme-NANs (excitation: 549 nm, emission: 563625 nm; measurements taken with a Horiba Jobin Yvon Fluorolog 3 series fluorometer.). TYE563 DNAzyme fluorescence values from the NANs were compared to a standard curve of the free
DNAzyme to obtain the final DNAzyme concentration in the DNAzyme-NAN sample. After
comparing the concentration of DNAzymes in the sample to a known concentration of NANs
present, it was found that there are roughly 2 DNAzymes per surfactant molecule (Figure 2.6),
suggesting that the NAN assembly and DNAzyme ligation are both highly efficient.
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Figure 2.6. Quantification of DNAzymes/NAN.
A) TYE563-labeled DNAzyme was ligated to the surface of the NAN. B) Standard curve of TYE563DNAzyme. C) Quantification assay results. After removal of unligated DNAzymes, fluorometric
measurements of the DNAzyme-NANs were taken. The intensity was compared to the standard curve
to obtain the concentration of TYE563 DNAzyme. This value was compared to a known concentration
of surfactant, giving approximately 2.3 DNAzymes per surfactant molecule.37
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Stability of unmodified DNAzyme on NAN surface. In order to achieve GATA-3 knockdown,
the DNAzyme must engage and cleave mRNA located in the cytoplasm of the cell. As the
DNAzyme was chemically unmodified, it became of interest to investigate the stability of the
nucleic acid on the NAN surface in the presence of nucleases. Due to the spherical nature of the
NAN and the dense coating of nucleic acids on the surface, it was hypothesized that the DNA
would show enhanced stability, as seen in other similar structures.38 DNAzyme-NANs were
incubated in 10% fetal bovine serum (FBS) in PBS at 37 °C for 1 hour, as FBS contains many of
the nucleases found in the cellular environment. After incubation, the resulting nucleic acid
mixture was amplified via 35 cycles of polymerase chain reaction (PCR), and the PCR product
was observed on an 8% denaturing polyacrylamide gel. It was found that the full length DNAzyme
was still present on the surface of the NAN, even after exposure to a mixture of nucleases (Figure
2.7). This means that the chemically unmodified DNAzymes experience enhanced stability on the
surface of the NAN. The enhanced stability is thought to be the result of steric hindrance of
nucleases due to the dense packing of the nucleic acids on the NAN surface.
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Figure 2.7. Stability assay scheme and results.
DNAzyme-NANs were incubated with 10% FBS for 1 hour. The products were then amplified through 35 cycles
of PCR and run on an 8% denaturing PAGE gel. The gel shows the presence of DNAzyme (DNz) even after
treatment with FBS, indicating the stability of the nucleic acid on the surface of the NAN. The DNz-Ext. band
indicates the PCR product of the anchor-DNAzyme.37

DNAzyme-surfactant conjugates and endosomal escape. As esterases are present in high
concentrations in cellular endosomes,10,11 it was hypothesized that the ester-crosslinked NANs
would undergo degradation after endocytosis, releasing individual DNAzyme-surfactant
conjugates. An in vitro assay was therefore designed to investigate the degradation of the NAN in
the presence of esterase and to visualize the degradation products. TYE665-labeled DNAzyme-
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NANs were incubated with 5 units of porcine liver esterase (in phosphate buffer) in a total volume
of 50 µL water for 1 hour, and the resulting products were run through a 3% agarose gel (Figure
2.8). Compared to the free DNAzyme and DNAzyme-NAN, the sample of DNAzyme-NANs
treated with esterase showed the presence of bands representing the DNAzyme-surfactant
conjugates.

Figure 2.8. Esterase treatment of DNAzyme-NANs.
After incubation of dye-labeled DNAzyme-NANs with esterase, the products were run in a 3%
agarose gel. The gel shows the difference between a free DNAzyme, the DNAzyme on the NAN
surface, and the cleavage products, which are individual surfactant-DNA conjugates.37
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As the esterase-mediated degradation of the NANs resulted in individual DNAzyme-surfactant
conjugates, it was hypothesized that this chemically tethered surfactant aided the endosomal
escape of the DNAzyme. To further study the effect of the surfactant tail, a synthetic lipoplex
system was designed. (Figure 2.9)

Figure 2.9. Design of a synthetic lipoplex to investigate the effect of the surfactant tail on endosomal
escape.
A) A 13 nm gold nanoparticle was first functionalized with thiolated DNA and thiolated PEG-DSPE lipid
in a 1:2 ratio. Dually functionalized mRNA was hybridized to the DNA on the surface via a bridge. The
functionalized AuNP was then encapsulated in DOPE, forming a mock lipid bilayer with the mRNA
buried within. B) TEM images of the assembled lipoplex construct.37
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The lipoplex system involved the functionalization of gold nanoparticle with thiolated DNA and
thiolated lipid. Truncated mRNA target was then hybridized to the thiolated DNA presented on
the surface via a bridge. The entire system was then encapsulated in a secondary lipid, resulting in
the target mRNA within a mock bilayer.

First, it was important to optimize the length of the bridge to allow for efficient hybridization while
still allowing for cleavage and dissociation of the mRNA truncate. Bridge sequences were
designed with varying lengths of overlap with the mRNA sequence: a 4-mer overlap, a 6-mer
overlap, and a 9-mer overlap. For the in-solution hybridization of mRNA to anchor, 4 µM bridge
was added to 2 µM mRNA truncate and 2 µM anchor in water. The solution was first heated at 70
°C for 5 minutes, then placed at 37 °C for 10 minutes. The solution was then sonicated for 20
minutes at room temperature to form the hybridized product. To investigate the DNAzyme activity
on hybridized mRNA, 5 µM free DNAzyme was added to 0.5 µM hybridization product. 10 mM
MgCl2 and 100 mM NaCl was added to a final volume of 50 µL. The solution was then mixed at
550 rpm at 37 °C for 4 hours. The resulting products were run on an 8% denaturing PAGE gel
(Figure 2.10). Cleavage of the mRNA truncate was visualized regardless of bridge length,
meaning that the degree of overlap didn’t negatively affect DNAzyme activity. Based on these
results, the 6-mer overlap bridge was used in the lipoplex system as it allowed for efficient
hybridization and cleavage of the truncate, while still allowing for dissociation of mRNA postcleavage.
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Figure 2.10. In-solution cleavage of mRNA hybridized to anchor with bridges of varying length.
After 4 hours at 37 °C with appropriate salts, the free DNAzyme was able to cleave the target mRNA,
regardless of bridge length. 1) free mRNA truncate 2) free mRNA truncate + DNAzyme 3) mRNA truncate
hybridized with 4-mer overlap + DNAzyme 4) mRNA truncate hybridized with 6-mer overlap + DNAzyme
and 5) mRNA truncate hybridized with 9-mer overlap + DNAzyme. Gel first scanned at 532 nm to visualize
Cy3 signal from RNA truncate only, then stained with SYBR and scanned at 473 allowing for visualization
of all nucleic acids present.

To prepare the lipoplex system, thiolated DNA and a thiolated poly(ethylene glycol)-1,2distearoyl-sn-glycero-3-phosphoethanolamine (PEG-DSPE) were added to 1 mL of citrate capped
gold nanoparticles (AuNP) in a 1:2 ratio. The solution was mixed at room temperature for 10
minutes. 25 mM NaCl was added to the solution 3 separate times, 10 minutes apart, with mixing
in between additions. The solution was then mixed at room temperature overnight. The
functionalized AuNPs were washed via centrifugation at 15,000 rpm for 20 minutes and
resuspended in water.
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The DNA on the surface of the gold nanoparticle served as an anchor to hybridize a 19-mer GATA3 mRNA truncate to the surface. The mRNA was dually-modified with both a Black Hole
Quencher (BHQ) and a fluorescein amidite (FAM) on its terminal ends, meaning it would have
limited fluorescence unless cleaved. For the hybridization, 5 µM mRNA and 10 µM bridge were
added 60 nM DNA anchor/DSPE-PEG functionalized AuNPs in a final volume of 50 µL. The
solution was heated at 70 °C for 5 minutes and cooled to 37 °C for 10 minutes, followed by
sonication at room temperature for 20 minutes. The solution was then placed at 37 °C for 3 hours.
AuNPs were washed via centrifugation at 15,000 rpm for 10 minutes and resuspended in water to
remove any free mRNA or bridge in solution.

After successful preparation of the anchor/DSPE AuNPs, it was important to investigate the ability
of the free DNAzyme to cleave the hybridized mRNA on the surface, as the mRNA is buried
within the lipids. For free mRNA, 10 nM BHQ-mRNA-FAM was added to 1 µM DNAzyme, 100
mM NaCl, and 10 mM MgCl2 in water to a final volume of 400 uL. Alternatively, for mRNA
hybridized to AuNP surface, 5 µL of functionalized AuNPs (0.75 nM by gold) was added to 1 µM
DNAzyme, 100 mM NaCl, and 10 mM MgCl2 in water to a final volume of 400 uL. The cleavage
of mRNA was measured as a function of fluorescence intensity, resulting from the separation of
the dye and quencher, measured with a Horiba Jobin Yvon Fluorolog 3 Series fluorometer.
Measurements were taken at 37 °C over 600 minutes (excitation: 470 nm, emission: 485-600 nm).
There was an increase in fluorescence intensity for both free mRNA and hybridized mRNA,
meaning that the activity of the DNAzyme was not affected (Figure 2.11).
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Figure 2.11. Cleavage of hybridized mRNA.
Cleavage of mRNA hybridized to the AuNP surface, measured as an
increased in relative fluorescence intensity. These results indicate that the
DNAzyme can efficiently cleave the mRNA hybridized to the AuNP.

Lastly, the entire construct was then encapsulated with dioleoylphosphatidylethanolamine (DOPE)
to form an immobilized lipid bilayer.39 For this encapsulation, 7 µL of 130 µM DOPE (1,2dioleoyl-sn-glycero-3-phosphoethanolamine) in chloroform was first added to a 1.5 mL Eppendorf
tube and dried in air for 30 minutes. 50 µL of hybridized DNA anchor/DSPE-PEG AuNPs was
added to the tube, and sonicated for 1 hour at room temperature.

Anchor and DSPE functionalized AuNPs and the DOPE encapsulated AuNPs were characterized
via agarose gel electrophoresis (Figure 2.12). AuNPs functionalized with anchor only were also
run in the gel as a comparison to the lipoplex, as the dense coating of negatively charged nucleic
acids on the surface results in the movement through the gel matrix. The limited movement of the
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anchor and DSPE lipid functionalized AuNPs in the second lane of the gel is expected. Although
the lipid structure has a net negative charge, the dense coating of hydrophobic lipids on the surface
limits the overall movement of the AuNP. Finally, the slight movement of the encapsulated
lipoplex system (lane 3) relative to the pre-encapsulated system (lane 2), represents the change in
surface composition after the addition of the DOPE layer.

Figure 2.12. Agarose gel characterization of lipoplex system.
1% agarose gel of AuNPs functionalized with thiolated DNA only (lane 1), AuNPs functionalized with
thiolated DNA and PEG-DSPE in a 1:2 ratio (lane 2), and the DNA/DSPE AuNPs encapsulated in DOPE
(lane 3). The red bands in the gel are due to the visualization of the <100 nm gold nanoparticles.

The stability of the lipoplex was investigated via disruption of the membrane and release of
mRNA. For this, varying concentrations of Triton X and sodium dodecyl sulfate (SDS) were tested
in their ability to break apart the lipoplex, as they are both detergents that are commonly used to
destabilize lipid membranes.40,41
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10 µL encapsulated lipoplex with Cy3-RNA hybridized was added to varying concentrations of
detergent (2%, 0.5%, and 0.01% Triton X and 2% and 0.5% SDS) in water. The solutions were
sonicated for 30 minutes at room temperature, and run on a 1% agarose gel (Figure 2.13). Only
2% SDS showed release of mRNA truncate. This result shows the stability of the lipoplex system
in the presence of surfactants.

Figure 2.13. Release of mRNA truncate after disruption of the lipoplex.
As seen by the mRNA band in the 1% agarose gel, only 2% SDS was
effective at disrupting the lipoplex system.

Finally, it was of interest to investigate the ability of DNAzyme-surfactants to cleave the mRNA
truncate in the lipoplex. In order to mimic the surfactant-DNAzyme product that resulted from
esterase-mediated degradation of the NAN, individual surfactant precursors were modified with
DNAzymes. These precursors consisted of disubstituted surfactant molecules that presented two
alkynes, in contrast to the trialkyl surfactants that made up the SCMs. As two of the alkynes in the
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trialkyl surfactant molecules are involved in the surface crosslinking of the nanocapsule, only one
site is available for DNA attachment. To form the DNA-surfactant conjugates, 100 µM thiolated
DNA anchor and 20 µM 2-hydroxy-4-(2-hydroxyethoxy)-2-methylpropiophenone (DHEMPP)
was added to 10 mM disubstituted surfactant in water in a total volume of 250 µL. The resulting
solution was placed in a Rhyonet reactor for 30 minutes with stirring. The resulting product was
purified via a Sephadex G-25 NAP-10 column. The ligation of DNAzyme to the DNA-surfactant
conjugates was achieved following a standard ligation protocol, where 20 µM GATA-3 DNAzyme
and 15 µM DNAzyme bridge were added to 10 µM purified anchor-surfactant, in a 1 anchor: 2
DNAzyme: 1.5 bridge ratio. After the ligation, the product was purified via a Sephadex G-25 NAP10 column and was analyzed by DLS measurements.

The DNAzyme-surfactant conjugates were challenged to cleave the mRNA target that was
embedded in the lipid bilayer system. To achieve this, the lipoplex construct was incubated with
either 1 µM free DNAzyme or the DNAzyme-surfactant conjugates in appropriate salt
concentrations (100 mM NaCl, 10 mM MgCl2) at 37 °C. NaCl is important in the correct folding
of the DNAzyme, as it helps shield the charge of the phosphate backbone, while Mg2+ is required
for the catalytic activity of the DNAzyme. mRNA cleavage was monitored as a function of
fluorescence intensity, measured with a Horiba Jobin Yvon Fluorolog 3 series fluorometer
(excitation: 470 nm, emission: 485-600 nm). Compared to the salt background sample, the
DNAzyme-surfactants showed an increase in fluorescence relative to the free DNAzyme,
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suggesting that the hydrophobic surfactant tail did assist the DNAzyme in accessing the mRNA
through the lipid bilayer (Figure 2.14).

Figure 2.14. Cleavage of mRNA in the lipoplex system with individual DNAzyme-surfactant
conjugates.
Compared to free DNAzyme and a salt-only background, the DNAzyme-surfactant conjugates
showed a greater increase in relative fluorescence. This indicates that the hydrophobic surfactant tail
aids the DNAzyme is accessing the mRNA truncate through the lipid bilayer.37

Endocytosis of DNAzyme-NANs and intracellular GATA-3 knockdown. Cellular uptake of
the DNAzyme-NANs was then evaluated via confocal microscopy. For these studies, a TYE665labeled DNAyzme was ligated to the surface of the NANs. The successful ligation was analyzed
through 3% agarose gel electrophoresis (Figure 2.15). Compared to the free TYE665-labeled
DNAzyme, the TYE665 DNAzyme-NANs were visualized as a higher band in the gel, indicative
of the larger size of the NAN vs. free DNA.
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Figure 2.15. Agarose gel of ligated DNAzymes.
3% agarose gel of free TYE665-labeled DNAzyme vs.
TYE665 DNAzyme-NANs. The size shift of the
DNAzyme-NAN indicates the successful ligation the
DNAzyme to the NAN surface.

Confluent MCF-7 cells were plated in an 8-well confocal chamber at 100,000 cells/mL and
incubated overnight. Cells were then incubated with either 250 nM free TYE665 DNAzyme or 1
µM TYE665 DNAzyme-NANs in OptiMEM for 4 hours at 37 °C. Free DNAzyme was transfected
into cells using Lipofectamine 2000. Prior to imaging, cell nuclei were stained with Hoechst
33342. Images were obtained with a Leica SP8 confocal microscope. MCF-7 cells were chosen in
these studies due to their expression levels of GATA-3.42 After the 4-hour incubation, confocal
images showed successful cellular uptake of the NANs (Figure 2.16).

53

Figure 2.16. Confocal microscopy.
Confocal microscopy images of MCF-7 cells treated with either free TYE665 DNAzyme
(transfected with Lipofectamine 2000) or TYE665 DNAzyme-NANs. The TYE665 signal (red
channel) in the cells indicates cellular uptake of the NANs. Scale bars are 20 µm.37

After confirming the endocytosis of the DNAzyme-NANs, the next step was to investigate the
ability of the DNAzyme to cleave target mRNA intracellularly. In order to assess the GATA-3
mRNA cleavage, confluent MCF-7 cells were treated with either 250 nM DNAzyme-NANs, 300
nM free DNAzyme, or 150 nM commercially available GATA-3 siRNA. It is important to note
that the free DNAzyme and siRNA were transfected into cells using Lipofectamine 2000, a
common transfection agent, while the DNAzyme-NANs did not require any transfection agents.
After a 4-hour incubation in OptiMEM, the mRNA expression levels were evaluated using
quantitative polymerase chain reaction (qPCR) after reverse transcription of isolated total cellular
RNA, isolated using a Qiagen RNeasy Plus Mini Kit. Treatment with DNAzyme-NANs resulted
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in a 60% knockdown of GATA-3 mRNA, which was comparable to both free DNAzyme and
siRNA (Figure 2.17).

Figure 2.17. GATA-3 mRNA expression in MCF-7 cells.
After treatment with 250 nM DNAzyme-NANs, there was a
60% reduction in mRNA expression relative to untreated cells.37

The persistence of knockdown after treatment with DNAzyme-NANs was also tested. It was
important to investigate the persistence of knockdown, as the DNAzyme on the NAN surface was
unmodified. This means that the DNAzyme must retain its full structure long enough to bind and
cleave the target mRNA. While modifications to DNAzymes can increase stability and result in
longer half-lives (ranging from 6.5 – 25 hours),43 chemically unmodified DNAzymes have been
shown to have a short half-life (t1/2 = 70 minutes) in serum.44 In contrast, heavily chemically
modified siRNA has been shown to achieve mRNA knockdown through 5 days, and in some cases
up to 10 days, after transfection into HeLa cells.45 It was found that the DNAzyme-NANs were
capable of mRNA cleavage that lasted over 12 hours (Figure 2.18). By 48 hours after treatment,
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the mRNA levels began to recover, although they were still lower that the levels of untreated cells.
These results highlight the chemical stability of the DNAzyme on the NAN surface.

Figure 2.18. Persistence of GATA-3 mRNA cleavage after
treatment with DNAzyme-NANs.
Knockdown of mRNA lasted over 12 hours after initial
DNAzyme treatment, and started to recover at 48 hours.37

To investigate the specificity of the DNAzyme for its mRNA target, four mutations were
introduced into the flanking region (Figure 2.19). As the mutations were not in the catalytic loop,
this allowed for loss of specificity, but not activity. Thus, the DNAzyme should have been able to
cleave any bound mRNA. MCF-7 cells treated with 250 nM mutated DNAzyme-NANs showed
limited mRNA cleavage (Figure 2.19), demonstrating the high degree of specificity that the
DNAzyme has for the target mRNA.
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Figure 2.19. mRNA expression levels after treatment with mutated DNAzyme-NANs.
After introducing 4 mutations in the flanking regions of the DNAzyme, resulting in loss of specificity
for the GATA-3 mRNA target, there was limited mRNA cleavage.37

Another way to investigate the DNAzymes ability to cleave target mRNA is through comparison
of relative protein expression levels via a western blot. Western blots are commonly used to
visualize specific proteins through antibody-antigen recognition, and are typically used alongside
qPCR, as they can correlate the knockdown of mRNA to the loss of translated protein. As the
protein of interest was GATA-3, the primary antibody was human anti-GATA-3. Human antiGAPDH was also utilized as a housekeeping gene. The secondary antibody was conjugated to a
Cy3, allowing for visualization.
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Figure 2.20. Western blot schematic.
After cell lysis, proteins are run in an SDS-PAGE gel and separated by size.
Proteins are then transferred onto a nitrocellulose membrane. Primary
antibodies are introduced and bind to the protein of interest, GATA-3. Cy-3
labeled secondary antibodies are then added, and bind to the primary antibody.

For these studies, confluent MCF-7 cells treated with 250 nM DNAzyme-NANs for 24, 48, and
96 hours. The extended treatment times were necessary to see the loss of GATA-3 protein resulting
from the cleavage of GATA-3 mRNA. After incubation, cells were trypsinized and pelleted. Cells
were resuspended in 250 µL cold Pierce IP Lysis Buffer (ThermoScientific), and transferred to a
1.5 mL Eppendorf tube. The sample was briefly vortexed and kept on ice for 30 minutes. The
sample was then centrifuged at 4 °C, 12,000 rpm for 10 minutes. Supernatant was removed and
kept on ice until used.

Prior to running a western blot, it was important to determine the total protein concentration in the
lysate. This was investigated via a Pierce BCA Protein Assay Kit, following the protocol provided
by the manufacturer. Briefly, 25 µL of each cell lysate sample was added to 200 µL working
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reagent (provided) in a 96-well plate. The plate was incubated at 37 °C for 30 minutes, and the
absorbance at 562 nm was measured. Total protein concentrations were then calculated based on
a standard curve of BSA absorbance.

For the western blot, all proteins present in a mixture of interest are first separated based on
molecular weight through SDS-PAGE gel electrophoresis. SDS is important as it coats all proteins
in a negative charge, allowing for separation by size only. 20 µL of 2 Laemmli buffer (Bio-Rad
Technologies) was added to cell lysate samples and water to a final volume of 40 µL. The amount
of cell lysate used in each sample varied, depending on total protein concentration. The sample
was run in a 12 % SDS PAGE gel at 120 V for 2 hours on ice. The separated proteins were then
transferred to a nitrocellulose membrane using the 3-minute transfer on a Bio-Rad Trans-Blot
Turbo Transfer System. Blocking of the membrane was achieved via incubation of the membrane
in a milk solution (1.25 g powdered milk in 25 mL 1x PBS) for 1 hour at 4 °C with shaking. The
blocking step is important as it prevents non-specific binding of the antibodies. The membrane
was rinsed with 1x PBS/Tween. For detection of GATA-3, 50 µL Human GATA-3 primary
antibody (HG3-31: sc-268, Santa Cruz Biotechnology) and 50 uL GAPDH primary antibody (G9: sc-365062, Santa Cruz Biotechnology) in 25 mL 1x PBS/Tween was added, and incubated with
shaking at 4 °C overnight. The membrane was again rinsed with 1x PBS/Tween. 50 µL Cy3
Donkey Anti-Mouse IgG secondary antibody (Jackson ImmunoResearch) in 25 mL 1x PBS/Tween
was added and allowed to incubate with shaking at room temperature for 3 hours. The membrane
was rinsed with 1x PBS/Tween and imaged.
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Figure 2.21. Western blot of proteins isolated from MCF-7 cells.
Wild type GATA-3 protein is 48 kDa, while the mutated GATA-3 protein can result
in a product at 40-42 kDa and another at 23 kDa. Compared to untreated cells,
DNAzyme-NAN treatment resulted in a decrease in GATA-3 protein at 24 and 48
hours after treatment, visualized in the decrease in band intensity. This qualitative
decrease in the expression of GATA-3 in MCF-7 cells support the mRNA
knockdown measured through qPCR analysis.

While there was a visible decrease in the GATA-3 protein expression between untreated and
treated cells (Figure 2.21), we chose to quantify total mRNA levels as a metric for gene
expression, as MCF-7 cells have been shown to express a truncated GATA-3 protein (37-42 kDa)
with almost no expression of the wild-type 48 kDa GATA-3 protein.42 The mutation of GATA-3
in the MCF-7 cell line also results in a 23 kDa GATA-3 protein present in many samples. Even
though it was difficult to be quantitative about GATA-3 protein knockdown, these results
qualitatively supported the mRNA knockdown results observed by qPCR.
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Overall, the DNAzyme-NANs showed cellular uptake without the use of common transfection
agents, reinforcing the hypothesis that the NAN undergoes cellular endocytosis due to its SNAlike design. The cleavage of GATA-3 mRNA as seen by real-time qPCR and the loss of the GATA3 protein shown in the western blot, along with the persistence of mRNA cleavage over 12 hours,
suggests enhanced stability of the chemically unmodified DNAzyme on the NAN surface in the
cellular environment.

Summary
Taken together, these results show the NAN is a promising system for the intracellular delivery of
therapeutic nucleic acids for gene regulation. DNAzyme-NANs undergo endocytosis without the
use of transfection agents, as seen by confocal microscopy. Additionally, the degradation of NANs
results in the release of individual DNAzyme-surfactant conjugates, which have the potential to
aid in endosomal escape of the nucleic acid. Finally, DNAzyme-NANs show efficient intracellular
cleavage of GATA-3 mRNA and loss of GATA-3 protein.
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Chapter 3
Towards in vivo studies: GATA-3 specific DNAzyme-NANs in the treatment of
inflammation
Adapted from: Gavitt, T. D.; Hartmann, A. K.; Mara, A. B.; Szczepanek, S. M.; Rouge, J. L. A
GATA3-Targeting Nucleic Acid Nanocapsule for the Treatment of Allergic Lung Inflammation
in a Mouse Model of Asthma. In preparation.

Introduction
The main inflammatory response associated with asthma has been shown to be dominated by T
cells and eosinophils.1 T cells are lymphocytes that play a central role in adaptive immunity and
defense against pathogens. T cells are generated in the thymus and contain antigen-specific
receptors on their surface. Naïve T cells circulate throughout the body until they encounter their
specific antigen. The activation of T cells is an antigen-dependent process in which the T cell
receptor (TCR) binds a specific antigen presented by the major histocompatibility complex (MHC)
on the surface of antigen presenting cells (APCs). T cells can be divided into two subsets, cytotoxic
T cells (CD8) and helper T cells (CD4). This differentiation is determined by the binding of coreceptors to the MHC. The CD8 co-receptors of cytotoxic T cells will bind to MHC class I, while
the CD4 receptors of helper T cells bind to MHC class II. The CD4+ T cells can then further
differentiate into various subsets, including T helper type 1 (Th1), T helper type 2 (Th2), and T
helper type 17 (Th17) cells.2

The main function of Th1 cells is the activation of macrophages and control of cell-mediated
immunity, typically against intracellular infections through the production of interleukin-2 (IL-2),

65

interferon-gamma (IFN-g), and tumor necrosis factor-beta (TNF-b).3 Alternatively, Th2 cells are
responsible for eosinophil activation and antibody production, caused by the production of various
interleukins, including IL-4, IL-5, and IL-13.4 Th2 cells have also been shown to be responsible
for the development of asthma,3 and are upregulated in the airways of patients suffering from
asthma.5,6 Th17 cells are mainly characterized by the production of IL-17, which is a proinflammatory cytokine that is thought to play a role in many immune-mediated diseases, including
rheumatoid arthritis, inflammatory bowel disease, and asthma.7

Overall, CD4+ T cells have been shown to be a critical component of the inflammatory response
of asthma. Specifically, Th2 cells are responsible for the release of IL-4, IL-5, and IL-13, all of
which contribute to airway hyperresponsiveness and the differentiation and influx of eosinophils.6
Importantly, IL-4 serves as a regulator of IgE-mediated and eosinophil-mediated immune
responses, and promotes mucus secretion and the differentiation of Th2 cells.8

GATA-3 is a transcription factor that is responsible for the differentiation of naïve CD4+ T cells
into T helper type 2 (Th2) cells (Figure 3.1), and has been shown to be upregulated during this
differentiation of Th2 cells.9 GATA-3 binds the DNA sequence WGATAR, where W is either A
or T and R is either A or G10 in the promoter region of both IL-511 and IL-13 genes.12 Although
GATA-3 does not bind the promoter region of IL-4, studies have shown that GATA-3 is indirectly
responsible for the production of IL-4 as it induces the expression of other transcription factors
that in turn act on the IL-4 promoter.13
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Figure 3.1. The role of GATA-3 in T cell differentiation.37
After encountering a specific antigen, naïve T cells become CD4+ T cells. IL-4 present
in the cell environment induces differentiation into Th2 cells, which expresses GATA3.14 GATA-3 induces the production of pro-inflammatory cytokines including IL-4, IL5, and IL-13.
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Matrix metalloproteinases (MMPs) are a family of extracellular proteases that have been shown to
be involved in the regulation of inflammation.15 MMP cleavage of protein substrates can either
promote or suppress inflammation via control of leukocyte migration, and MMPs have been shown
to be upregulated in inflammatory diseases.15 Additionally, MMPs play a key role in the
degradation of airway extracellular matrix (ECM), which contributes to airway remodeling in
airway inflammatory diseases, including asthma.16,17 Specifically, MMP9 has been shown to be
upregulated in patients with asthma.18,19 Herein, it was of interest to make the NAN more
biochemically specific by incorporating the peptide substrate for MMP9 (CGPLGLAGGERDGC)
as the crosslinker.20 This would result in the degradation of the NAN in response to the increased
concentration of MMP9 in asthma patients, allowing for disease specific gene regulation.

In this chapter, the in vitro studies of GATA-3 specific DNAzyme-NANs were expanded to human
primary immune cells. The cellular uptake properties are investigated in human peripheral blood
mononuclear cells (PBMCs) through confocal microscopy and flow cytometry. DNAzyme activity
was also investigated in both human PBMCs and Jurkat cells via qPCR measurements of mRNA
expression. Finally, the in vivo activity of the DNAzyme-NANs was evaluated using a house dust
mite (HDM) associated allergic airway disease mouse model.

Preparation of DNAzyme-functionalized NANs. To make the surface crosslinked micelles
(SCMs), 1.0 mg of tri-alkyl modified surfactant (0.005 mmol) was first self-assembled into
micelles in water. Crosslinking of the micelles was done via a UV-mediated thiol-yne reaction
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between the cysteine groups of the peptide crosslinker (CGPLGLAGGERDGC) and the alkyne
groups of the surfactant (Scheme 3.1).

Scheme 3.1. Stepwise assembly of peptide crosslinked DNAzyme-NANs.
Individual surfactant molecules are self-assembled into micelles in water. The micelles are then crosslinked
with a peptide crosslinker via a UV-mediated thiol-yne reaction between the cysteine groups of the peptide
and the alkyne presented by the surfactant, forming SCMs. The remaining alkyne on the surface is further
functionalized with thiolated DNA via a second UV-mediated thiol-yne reaction. Finally, monophosphorylated
DNAzyme is enzymatically ligated to the surface of the NAN using T4 DNA ligase.

The peptide crosslinker (Figure 3.2) used in the synthesis acts as a substrate for the MMP9
enzyme.20 As previously shown by our group, the substrate-specific peptide crosslinker allows for
a more specific degradation vs. the esterase-responsive NAN.21 MMP9 was chosen specifically
due to its upregulation in asthma patients.19
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Figure 3.2. Peptide crosslinker structure.

The proteolytic cleavage of the crosslinker is between the 4th and 5th amino acid of the substrate,
resulting in two shorter peptides (CGPLG and LAGGERDGC) on either end of the surfactantnucleic acid conjugate.22 Although this results in larger degradation products relative to the
original ester crosslinker, the two peptides contain a high degree of hydrophobic residues, which
have been shown to make up cell penetrating peptides.23,24

After self-assembly and crosslinking, SCMs were purified via size exclusion chromatography
using a Sephadex G-25 NAP-10 column, and the fractions were analyzed by dynamic light
scattering (DLS) and zeta potential measurements. SCMs had an average size of approximately 23
nm and a surface charge of roughly + 35 mV. (Figure 3.3).
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Figure 3.3. DLS and zeta potential measurements of SCMs.
Full width at half maximum for the size distribution was calculated to be 22.1.

Table 3.1. DNA and RNA sequences.
Blue represents monophosphorylation for T4 DNA ligase recognition.
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To form the nucleic acid nanocapsules (NANs), thiolated DNA was added to the remaining alkyne
group on the SCM surface via a UV-mediated thiol-yne reaction, in a 1: 2 NAN: DNA ratio
(Scheme 3.1). After successful addition of thiolated DNA on the surface, the NANs were roughly
26 nm and -32 mV (Figure 3.4). The shift in charge is due to the addition of negatively charged
nucleic acids on the surface of the nanocapsule.

Figure 3.4. DLS and zeta potential measurements of NANs.
Full width at half maximum for the size distribution was calculated to be 22.8.
NANs were further functionalized with a chemically unmodified GATA-3 DNAzyme through
enzymatic ligation (Scheme 3.1). After the ligation, DNAzyme-NANs were purified using a
Sephadex G-25 NAP-10 column, and the fractions were characterized via DLS measurements. The
average size shifted to approximately 49 nm, indicating the successful ligation of the DNAzyme
to the surface of the NAN (Figure 3.5).
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Figure 3.5. DLS of peptide crosslinked DNAzyme-NANs.
Full width at half maximum for the size distribution was
calculated to be 30.6.
GATA-3 mRNA cleavage in MCF-7 cells. After synthesis and characterization, it was important
to first investigate whether the peptide crosslinked DNAzyme-NANs could achieve intracellular
cleavage of GATA-3 mRNA, as the peptide crosslinker is significantly longer than the original
ester crosslinker. Additionally, the proteolytic cleavage of the peptide substrate differs
mechanistically from the esterase-mediated degradation of the ester crosslinker. Thus, the
efficiency of mRNA cleavage could be significantly altered with the peptide crosslinker.

For these studies, MCF-7 cells were placed in a 6-well plate at 100,000 cells/mL and incubated
overnight at 37 °C and 5% CO2. Cells were then treated with either 250 nM PEG crosslinked
DNAzyme-NANs or 250 nM peptide crosslinked DNAzyme NANs for 4 hours. PEG crosslinked
NANs were used as a control in the experiment as the PEG crosslinker does not allow for
degradation of the NAN. Thus, the PEG DNAzyme-NANs should remain intact in cellular
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endosomes. After incubation, cellular RNA was isolated using a Qiagen RNeasy Mini Plus Kit,
and RT-qPCR was utilized to evaluate relative mRNA concentrations. The PEG crosslinked
DNAzyme-NANs showed approximately 30% knockdown of GATA-3 mRNA relative to
untreated cells (Figure 3.6). In contrast, the peptide crosslinked DNAzyme-NANs showed
approximately 52% knockdown of mRNA, which is significantly higher than that of the PEG
NANs.

Figure 3.6. GATA-3 mRNA expression.
GATA-3 mRNA cleavage in MCF-7 cells treated with PEG crosslinked
DNAzyme-NANs or peptide crosslinked DNAzyme NANs. Peptide
crosslinked DNAzyme-NANs resulted in significantly lower mRNA
expression levels vs. PEG crosslinked DNAzyme-NANs, as they are able
to degrade and effectively enter the cytosol.

In vivo studies with DNAzyme-NANs. As the DNAzyme-NANs showed significant knockdown
of GATA-3 mRNA in vitro, it was of interest to investigate their activity in vivo. All in vivo studies
were done through a collaboration with Dr. Steven Szczepanek (University of Connecticut,
Department of Pathobiology and Veterinary Science).
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House dust mite (HDM) extract is a commonly used allergen in mouse models of allergic airway
disease that results in elevated airway inflammation and airway hyperresponsiveness.25 HDM
exposure has been shown to result in the significant upregulation of GATA-3 and the increased
differentiation and activation of CD4+ T cells.26 Additionally, there is an increase in Th2
associated cytokines, including IL-4, IL-5, IL-13, present in mice after HDM treatment.27

Prior to in vivo studies, it was of interest to evaluate the activity of the DNAzyme-NANs in the
presence of the HDM solution. This was important as the DNAzyme was premixed with the HDM
mixture prior to administration, and HDM contains nucleases that could rapidly degrade the
chemically unmodified DNAzyme before it has time to reach its target. 1 µM DNAzyme-NANs
were incubated with 0.5 µM cy3-labeled mRNA truncate, 10 mM MgCl2, and 100 mM NaCl in
varying concentrations of HDM or PBS. The solution was mixed at 37 °C and 550 rpm. Aliquots
were taken at 4 hr and 12 hr and run in an 8% denaturing PAGE gel. The DNAzyme-NANs showed
cleavage of the mRNA truncate (Figure 3.7), meaning that the activity of the DNAzyme is not
affected by the presence of the house dust mite solution.
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Figure 3.7. Activity of DNAzyme-NANs in the presence of house dust mite (HDM)
solution.
After 12 hours, mRNA truncate was completely cleaved, even in the presence of 50%
HDM. These results show that the HDM solution does not affect the DNAzyme-NANs
activity, meaning DNAzyme-NANs can be co-delivered with HDM solution in the in
vivo studies.

After confirming the activity of the DNAzyme-NANs in the HDM mixture, the activity of
DNAzyme-NANs was investigated in an HDM-associated allergic airway disease (AAD) mouse
model. Prior to treatment, lyophilized HDM antigen (Dermatophagoides farinae and
Dermatophagoides pteronyssinus) was resuspended in PBS to a final concentration of 1 µg/µL.
Mice treated with HDM were given 25 µL of the 1 µg/µL HDM solution and 25 µL PBS.
Alternatively, mice treated with both HDM and DNAzyme-NANs were given a 1:1 mixture (25
µL of 1 µg/µL HDM solution + 25 µL NANs in PBS).

In an initial in vivo study, fifteen 9-week old mice were split into 3 groups (5 mice each) and
treated with either PBS, HDM solution, or HDM solution + 250 nM DNAzyme-NANs in a final
volume of 50 µL. Mice were treated intranasally for five weeks, five days a week. After the five-
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week period, bronchoalveolar lavage (BAL) was performed to analyze cells present in the lungs.
For these studies, BAL fluid was spun down on microscope slides and stained with KwikDiff stain,
which is a methylene blue and eosin based stain that allows for the differentiation of neutrophils,
eosinophils, basophils, and monocytes.28 The percentage of eosinophils present in DNAzymeNAN treated mice relative to the HDM-only and PBS-only mice was used to determine the severity
of allergic airway disease. After treatment with the HDM mixture, the BAL fluid contained
approximately 15% eosinophils (Figure 3.8). However, when treated with HDM + 250 nM
DNAzyme NANs, BAL fluid contained an average of 5% eosinophils (Figure 3.8). Although the
DNAzyme-NANs showed an improvement in disease severity, the percentage of eosinophils
present in the HDM only mixture was lower than expected.29

Figure 3.8. Results of initial in vivo study.
The percentage of eosinophils is relative to the severity of allergic airway disease.
After treatment with HDM solution only, there was an increase in the percentage
of eosinophils to an average of 17%. However, mice that received DNAzymeNANs and HDM solution showed lower eosinophil percentages (an average of
6%), meaning the DNAzyme-NANs showed successful improvement in disease
severity.
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Since the batch of HDM solution utilized in the initial study was on the older side, it was then of
interest to use a fresh HDM mixture to investigate whether a stronger eosinophil response could
be generated. It was also of interest to evaluate a wider range of DNAzyme-NAN concentrations.
Additionally, it was important to investigate the effect of DNAzyme-NAN in both male and female
mice, as differences in gene expression and cytokine concentrations have been reported.30

For this study, eighty 9-week old mice (40 male, 40 female) were split into groups of 10 mice each
(5 male, 5 female) and were intranasally treated with either PBS only, HDM only, 250 nM
DNAzyme-NAN only, 25 nM DNAzyme-NAN + HDM, 125 nM DNAzyme-NAN + HDM, 250
nM DNAzyme-NAN + HDM, 1250 nM DNAzyme-NAN + HDM, or 2500 nM DNAzyme-NAN
+ HDM in a final volume of 50 µL. Mice were treated five days per week for five weeks. BAL
fluid was collected and analyzed for the presence of eosinophils. When eosinophil counts were
separated by sex, there was a significant decrease in the percentage of eosinophils for males treated
with all concentrations of DNAzyme-NANs compared to the HDM only control (Figure 3.9).
However, in the female group, while some mice showed lower eosinophil counts after DNAzymeNAN treatment, overall there was no significant difference compared to the HDM only control
(Figure 3.9). Additionally, there was a lower response of the female mice to the HDM mixture, as
there was only an average of 30% eosinophils present.
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Figure 3.9. Eosinophil percentages in male and female mice.
For the males, there was a significant improvement in the eosinophil percentage for all concentrations
of NANs tested relative to the HDM only group. However, the female group lacked statistically
significant differences between the DNAzyme-NAN and HDM only groups. Additionally, the
females on average showed a lower response to the HDM mixture.

We were excited to find that overall, when the data from the male and female mice was combined,
all concentrations DNAzyme-NAN treatments showed a significant improvement in the severity
of allergic airway disease, as the average eosinophil counts present in BAL fluid were all below
20%, compared to an average of 40% for the HDM only group (Figure 3.10). Importantly, there
was not an increase in eosinophils when mice were treated with 250 nM NAN only, meaning that
the NANs themselves do not cause airway inflammation, despite being composed of cationic
surfactants. These results are highly encouraging, considering the DNAzyme is not chemically
modified in any way, and still provided a significant decrease in airway eosinophilia.
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Figure 3.10. Combined eosinophil data.
Despite outliers present in the data, all concentrations of NANs tested showed
a significant reduction in the percentage of eosinophils relative to the HDM
only group. This shows that the DNAzyme-NANs were successful in the
reduction of the severity of allergic airway inflammation. Also, mice treated
with 250 nM DNAzyme-NANs only did not have an increase in the percentage
of eosinophils after treatment, meaning that the NANs themselves do not
contribute to airway inflammation.

Cellular uptake of DNAzyme-NANs in human immune cells. With the encouraging results from
the in vivo studies, it became of interest to study the uptake and activity of DNAzyme-NANs in
human immune cells. For these studies, human primary peripheral blood mononuclear cells
(PBMCs) were utilized. PBMCs were chosen as they play a significant role in the immune system
and contain a mixture of lymphocytes and monocytes, allowing for the investigation of which
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human immune cells take up NANs.31 Importantly, PBMCs contain CD4+ T cells, which are the
primary target cells for the DNAzyme-NANs. Traditionally, primary cell lines have been shown
to be difficult to transfect,32 and transfection of lymphocytes has been shown to lead to high levels
of cellular apoptosis.33 However, there is evidence that SNA-like structures can successfully
transfect primary immune cells.34

The cellular uptake of NANs by human immune cells was investigated through confocal
microscopy and flow cytometry. PBMCs purchased from American Tissue Culture Center
(ATCC) were thawed and immediately resuspended in cold RPMI 1640 supplemented with Lglutamine and 10% FBS. Cells were then split into tubes containing approximately 1 million
cells/mL. PBMCs were then incubated with 250 nM TYE665 DNAzyme-NANs for 1 hour at 37
°C. After treatment, PBMCs were centrifuged at 1500 rpm for 5 minutes at 4 °C. Supernatant was
removed and pellet was stored on ice. 2.5 µL Fc block in 2 mL PBS was added to each pellet and
incubated on ice for 10 minutes. Receptor-specific antibodies (Table 3.2) were added and
incubated on ice for 1 hour. The antibodies were used as specific cell markers, allowing for the
differentiation between the various monocytes and lymphocytes present in the PBMC mixture.

81

Table 3.2. Cell specific antibodies used in flow cytometry and
confocal microscopy.
Each antibody was labeled with a different dye to allow for
differentiation between cell types.

After incubation with the antibodies, 5 mL FACS buffer (1x PBS supplemented with 1% bovine
serum albumin (BSA)) was added and cells were centrifuged at 1500 rpm for 5 minutes at 4 °C.
The supernatant was removed and cell pellet was resuspended in 200 µL of 4% paraformaldehyde
in PBS to fix cells. Cells were incubated at room temperature for 30 minutes, mixed, and
centrifuged at 1500 rpm for 5 minutes at 4 °C. The supernatant was removed and pellet was
resuspended in 2.5 mL FACS buffer. Cells were stored at 4 °C until flow cytometry. For confocal
microscopy, 25 µL of fixed PBMCs were placed on a microscope slide, covered with a coverslip,
and stored at 4 °C until imaging.
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Confocal images showed the presence of DNAzyme-NANs in monocytes and CD4+ T cells, as
seen by the colocalization of the TYE665 DNAzyme signal (red) with the anti-CD14 antibody
(yellow) and anti-CD4 antibody (green), respectively (Figure 3.11).

Figure 3.11. PBMC confocal microscopy images.
Confocal microscopy images of PBMCs showing uptake of DNAzyme-NANs (red channel) by both
monocytes (yellow channel) and CD4+ T cells (green channel). Scale bars are 20 µm.

Flow cytometry was then used to be more quantitative about the uptake of NANs by the different
immune cells present in the PBMC mixture. The results of flow cytometry showed that of the
monocyte population (CD14+ CD19-), approximately 97% showed DNAzyme-NAN uptake,
while approximately 23% of CD4+ helper T cells (CD3+ CD4+) internalized the DNAzymeNANs (Figure 3.12). In contrast, less than 0.5% of CD8+ T cells (CD3+ CD8+) were shown to
have a positive DNAzyme-NAN signal (Figure 3.12). This data suggests that the DNAzyme
NANs are capable of cellular uptake by human primary immune cells. The high rate of NAN
positive monocytes was unsurprising, as monocytes are circulating precursors to macrophages.
Importantly, 23% of all CD4+ T cells in the population were NAN positive. As CD4+ T cells are
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the main GATA-3 expressing cells in the immune system, they are the main target of the
DNAzyme-NANs. Additionally, because the NANs were added to PBMCs in media supplemented
with 10% FBS, the visualization of signal in both the confocal images and the flow cytometry data
confirms the stability of the DNAzyme on the NAN surface, even in the presence of nucleases.

Figure 3.12. Flow cytometry data of PBMCs treated with DNAzyme-NANs.
Of the entire population, monocytes showed the highest rate of uptake, as 97.1 % of monocytes were
NAN positive. Of the CD4+ T cells, which are the cells of interest in this study as they express GATA3, 23.2% were NAN positive. Finally, less than 1% of CD8+ cells were NAN positive.

GATA-3 knockdown in human T cells. To better investigate the effect of the DNAzyme-NANs
in human immune cells, CD4+ T cells were isolated from the PBMC mixture using Fluorescence
Assisted Cell Sorting (FACS), performed on a BD FACSAria II Cell Sorter. PBMCs (ATCC) were
thawed and immediately resuspended in cold RPMI 1640 supplemented with L-glutamine and
10% FBS to a final concentration of 2 million cells/mL. The cells were then washed with cold
FACS buffer, blocked with Human BD Fc Block for 15 minutes, and stained in the dark with anti-
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human CD3 AF700 and anti-human CD4 BV21 on ice for 20 minutes. Cells were then washed and
separated via FACS.

Isolated CD4+ T cells were incubated with 250 nM DNAzyme-NANs in RPMI 1640 (without
FBS) for 4 hours and 12 hours at 37°C and 5% CO2. Total cellular RNA isolation was carried out
using a Qiagen RNeasy Plus Mini Kit, following protocol provided by the manufacturer. Reverse
transcription was carried out using Bio-Rad iScript Reverse Transcription Supermix, and RTqPCR was performed with iTaq Universal SYBR Green Supermix and appropriate primers.

While there was no change in the GATA-3 mRNA expression level after a 4-hour incubation with
DNAzyme-NANs, there seems to be minor decrease in the relative mRNA expression after a 12hour treatment (Figure 3.13). However, the relatively low expression of GATA-3 in the CD4+ T
cells isolated from healthy patients may not allow for a significant reduction of GATA-3 in treated
cells vs. untreated cells.35

Figure 3.13. Relative GATA-3 mRNA expression levels of
isolated CD4+ T cells after treatment with DNAzyme NANs.
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It was then of interest to investigate the ability of the DNAzyme-NANs to achieve GATA-3
knockdown in Jurkat cells, which is a human-derived immortalized T lymphocyte cell line that
expresses GATA-3.36 For these experiments, Jurkat cells were incubated with 250 nM DNAzymeNANs in RPMI 1640 + 10% FBS for 4 hours, 24 hours, and 48 hours. RNA isolation at each time
point was carried out using a Qiagen RNeasy Plus Mini Kit, following protocol provided by the
manufacturer. Reverse transcription was carried out using Bio-Rad iScript Reverse Transcription
Supermix, and RT-qPCR was performed with iTaq Universal SYBR Green Supermix and
appropriate primers.

There was a significant decrease in GATA-3 expression in Jurkat cells incubated with 250 nM
NANs for all time points investigated (Figure 3.14), with a maximum reduction of GATA-3
mRNA expression at 24 hours.

Figure 3.14. GATA-3 mRNA knockdown in Jurkat cells.
Significant knockdown of GATA-3 mRNA was achieved in all time
points investigated (*p < 0.05). Error bars represent standard error of
the mean (SEM), with N of at least 3 trials.
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Summary
In this chapter, the ester-based crosslinker was replaced with a peptide substrate for MMP9, a
protease upregulated in asthma. The peptide crosslinked DNAzyme-NANs showed cleavage of
GATA-3 mRNA in MCF-7 cells, meaning that the peptide crosslinker still allowed for endosomal
escape of the nucleic acid into the cytosol. Additionally, DNAzyme-NANs showed significant
improvement on disease severity in an in vivo model of allergic airway disease. Furthermore,
confocal microscopy and flow cytometry showed the successful cellular uptake of NANs by
human primary immune cells. Importantly, CD4+ T cells showed significant uptake of DNAzymeNANs. As CD4+ T cells express GATA-3, they are the primary target for the DNAzyme-NANs.
Finally, DNAzyme-NANs showed a slight reduction in GATA-3 mRNA expression in isolated
CD4+ T cells after a 12-hour treatment, and a significant reduction in GATA-3 mRNA expression
in Jurkat cells after all treatment times investigated (4-hour, 24-hour, and 48-hour). Overall, the
peptide crosslinked DNAzyme-NANs show promise for disease-specific gene regulation.
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Chapter 4
Synergistic delivery of an Au(III) metallodrug and siRNA using a NAN
Adapted from: Hartmann, A. K.; Gudipati, S.; Pettenuzzo, A.; Ronconi, L.; Rouge, J. L.
Chimeric siRNA-DNA Surfactants for the Enhanced Delivery and Sustained Cytotoxicity of a
Gold(III) Metallodrug. Bioconjugate Chem. 2020, 31, 1063-1069.

Introduction
Metallodrugs, specifically platinum (II)-based metallodrugs, have become increasingly popular in
the treatment of various cancers, as they lead to high levels of tumor cell death. Approved by the
FDA in 1978, cisplatin is one of the most well-known and widely used DNA-damaging anti-cancer
metallodrugs. Cisplatin, or cis-diamminedichloroplatinum (II), is a square planar, platinum-based
compound that contains four ligands, two amines and two chlorides. The chloride ligands play an
important role in the activity and toxicity of cisplatin.1 Due to the relatively high concentration of
chloride in the blood (100 mM), the chloride ligands of the cisplatin molecule remain attached to
the platinum atom in the center of the drug.2 However, once inside the cell, the lower chloride
concentration (4-20 mM) results in the exchange of the chloride ligands for water molecules.3 The
aquated form of the drug is considered to be “activated” as it is a potent electrophile that can
covalently bind to the nitrogen in the N7 position of guanine (Figure 4.1).3,4 The chemical
crosslinking of cisplatin with DNA results in the inhibition of transcription, replication, and cell
division, along with the interference of DNA repair mechanisms, all leading to cellular
apoptosis.3,5
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Figure 4.1. Overview of cisplatin activity.
Intracellularly, the two chloride ligands of cisplatin are exchanged with water, creating the
diaqua species. This “activated” molecule then interacts with the N7 position of guanine in
DNA.

However, despite its widespread use, there are many drawbacks associated with cisplatin. First,
the use of cisplatin is associated with severe side effects, as various types of rapidly dividing cells
take up cisplatin.2 Specifically, cisplatin has shown to induce damage to the liver, kidneys, and
neurons.6,7 Additionally, many patients show eventual drug resistance to cisplatin.8

In an attempt to build on the activity but avoid the major off-target toxicity of cisplatin, various
other platinum(II) compounds have been synthesized. Carboplatin is most similar to cisplatin in
its structure and mechanism of action, as it also binds cellular DNA. However, carboplatin has
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been shown to exhibit slower DNA binding kinetics and less potency overall.3 While carboplatin
does not show any nephrotoxic effects, studies have shown that it causes myelosuppression, which
is a decrease in bone marrow activity that results in the production of fewer red blood cells.9

Alternatively, gold-based metallodrugs have gained interest as promising alternatives to traditional
platinum-based compounds, as gold(III) compounds exhibit similar structures to platinum(II)
compounds. Recent studies have shown that the gold complexes work via a DNA-independent
mechanism, as they have weaker interactions with DNA and mainly interact with cellular
proteins.10 It is hypothesized that bypassing the non-selective DNA damage pathway of cisplatin
and other platinum(II)-based compounds, many of the severe side effects can be avoided.

The cytotoxic activity of various gold compounds has been attributed to the inhibition of
thioredoxin reductase (TrxR). Thioredoxin reductase (TrxR) plays an important role in the redox
homeostasis of cells through the reduction of thioredoxin.11 Additionally, TrxR is involved in the
repair of oxidative damage and the regulation of cellular growth and apoptosis (Figure 4.2).12,13
Gold(III) metallodrugs can lead to the inhibition of TrxR as the gold atom of the metallodrug can
interact with the selenium atom of the selenocysteine present in the redox motif of the enzyme.14
The selenocysteine residue in the active site of TrxR has been shown to be essential to the activity
of the enzyme, as modification or removal of the residue results in complete inactivation (Figure
4.2).15 Importantly, the inhibition of TrxR leads to the accumulation of oxidized thioredoxin and
oxidative stress, promoting cellular apoptosis.16,17
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Figure 4.2. Thioredoxin reductase.
The general role of thioredoxin reductase is the reduction of thioredoxin,
which plays a key role in redox homeostasis and cellular control of
apoptosis. Au(III) metallodrugs inhibit the activity of thioredoxin reductase
by binding the active site, resulting in a buildup of oxidized thioredoxin
that leads to cellular apoptosis.

Recently, Ronconi and co-workers synthesized two Au(III) compounds, AP209 (AuIIIBr2(SSCInp-GlcN1)) and AP228 (AuIIIBr2(SSC-Inp-OEt)) (Figure 4.3).18 These gold(III)-dithiocarbamato
complexes were designed as promising alternatives to traditional platinum(II)-based drugs. The
dithiocarbamate ligands of the two metallodrugs are important to their structure, as
dithiocarbamates have been shown to lower the harmful toxicity and eventual resistance of
metallodrugs.18,19 One potential drawback of these gold(III) structures lies in their stability. Under
physiological conditions, the gold(III) ion is easily reduced to either gold(I) or gold(0).20 However,
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the addition of sulfur-containing ligands, particularly dithiocarbamates, on the surface has also
been shown to improve the stability of Au(III) complexes.20

Figure 4.3. Au(III) metallodrug structures.
Chemical structures for AP209 (AuIIIBr2(SSC-Inp-GlcN1)) and AP228 (AuIIIBr2(SSCInp-OEt)).18

Despite their promise as potential therapeutics, both of these compounds suffer from limited
solubility in an aqueous environment. In this chapter, the NAN construct is utilized for a more
efficient in vitro delivery of the Au(III) metallodrugs, as they can be encapsulated in the
hydrophobic core of the nanocapsule. This results in enhanced uptake and cytotoxic properties of
the metallodrug.

It was also of interest to co-deliver a therapeutic nucleic acid using the NAN to enhance the effect
of the metallodrug. It has been shown that co-delivery of anti-cancer drugs with therapeutic nucleic
acids for the downregulation of various genes can result in increased drug efficacy.21

Specifically, the downregulation of Bcl-2 has been shown to have cytotoxic effects on tumor cells,
and shows synergistic effects when co-delivered with common anti-cancer metallodrugs.22,23 Bcl-
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2 is a cell-survival gene that is involved in the regulation of cellular apoptosis and programmed
cell death. More specifically, Bcl-2 regulates the intrinsic, or mitochondrial, apoptotic pathway of
cells.24 Bcl-2 is important, especially in cancer pathways, as the regulation of apoptosis is crucial
to tumor formation.25 Thus, many types of cancer cells overexpress Bcl-2,26 and this
overexpression has been shown to contribute to the chemoresistance of cancer cells.27,28
Additionally, it has been shown that certain tumor cells can become dependent on Bcl-2 for
survival.29

To investigate the synergistic effects of the downregulation of Bcl-2 with the delivery of the
Au(III) metallodrug, the surface of the NAN was functionalized with Bcl-2 targeting siRNA. Small
interfering RNA, or siRNA, is a short double stranded RNA molecule that regulates the expression
of genes via RNA interference (RNAi). The mechanism of RNAi involves the degradation of
intracellular mRNA via the RNA-induced silencing complex (RISC). In RNAi, the anti-sense
strand of the siRNA duplex engages RISC, and the complex targets and degrades complementary
mRNA.

To achieve this mRNA degradation intracellularly, the siRNA duplex must be effectively
delivered. Herein, this is achieved through the functionalization of the NAN surface with siRNA
targeting Bcl-2, following a previously developed protocol for the ligation of siRNA to a DNAfunctionalized gold nanoparticle, which were shown to be effective at achieving intracellular gene
regulation.30 Using the NAN platform, the intracellular enzyme-mediated degradation of the
nanocapsule results in the release of siRNA-surfactant conjugates. Previous studies have shown
that conjugation of siRNA to various lipids can increase the bioavailability and improve the
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efficacy of siRNA.31,32,33 Based on previous results, it is hypothesized that the anti-sense strand of
the siRNA duplex can then dehybridize from the nucleic acid-surfactant conjugate and engage in
the RNA interference mechanism. This chapter aims to investigate the ability of the NAN construct
to effectively deliver both a hydrophobic Au(III) metallodrug along with chemically unmodified
siRNA, resulting in the synergistic effect of enhanced cytotoxicity of the drug.

Synthesis and characterization of metallodrug-loaded SCMs and NANs. For the successful
incorporation of the metallodrugs into the hydrophobic core of the NAN, solid AP209 or AP228
was first dissolved in DMSO. 12.5 µL of the 10 mM drug stock (.000125 mmol) was then added
to 1 mg tri-alkyl surfactant (0.005 mmol) in water and sonicated. The resulting solution was stirred
for 30 minutes at room temperature. To form the SCM, crosslinker was added to the
drug/surfactant mixture (Scheme 4.1). For the diazido PEG crosslinked nanocapsule, a coppercatalyzed click reaction was utilized to form the SCM. Alternatively, the peptide-substrate
crosslinker (CGFLGGLFGGFLGC) was incorporated into the nanocapsule via a UV-mediated
thiol-yne reaction.
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Scheme 4.1. Stepwise assembly of Au(III) metallodrug-loaded SCMs and NANs.
First, surfactant is dissolved in water to form micelles. Metallodrug in DMSO is added to allow for
incorporation into the hydrophobic core of the micelle. SCMs are formed via crosslinking of the micelle
through either a UV-mediated thiol-yne reaction or a copper(I) catalyzed click reaction. SCMs are further
functionalized with thiolated DNA via a UV-mediated thiol-yne reaction to form NANs.

For these studies, the peptide substrate crosslinker is specific for the cathepsin B enzyme.34
Cathepsin B is a protease that is present in high concentrations in late endosomes and lysosomes.
As the enzyme is optimally active at pH 5, it is hypothesized that the nanocapsule will not degrade
until it is endocytosed and late endosomes are formed. For the peptide crosslinker, the cleavage
site for the cathepsin B enzyme (GFLG) is repeated three times in the sequence in order to increase
the likelihood of nanocapsule degradation (Figure 4.4). The peptide is also modified with cysteine
residues on either end for the thiol-yne reaction.
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Figure 4.4. Structure of peptide crosslinker.
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Once fully formed, the SCMs were purified via centrifugation, as the drug-loaded nanocapsules
are dense enough to form a pellet (Figure 4.5). The free drug present in the solution is not pelleted
via centrifugation, allowing for the separation of any excess metallodrug.

Figure 4.5. Free metallodrug vs. metallodrug encapsulated
in SCMs after centrifugation.
The free drug in solution was not affected by centrifugation,
whereas the encapsulation of the drug in the core of the
SCM resulted in a pelleted sample.35

Purified SCMs were then characterized via DLS and zeta potential measurements. The average
size of the peptide crosslinked SCMs containing AP228 was 71.7 nm, with an average charge of
22.4 mV. Alternatively, the average size and charge of the AP228 PEG crosslinked SCMs were
28.4 nm and 46.1 mV, respectively. While the charge of the SCMs containing AP209 were similar,
the size was slightly larger, likely due to the larger size of the AP209 metallodrug (Table 4.1).
Overall, the large size of the SCMs, regardless of which metallodrug was loaded in the core,
seemed to suggest dimerization and aggregation of the nanoparticles.
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Thiolated DNA was then added to the surface of the SCM via a UV-mediated thiol-yne reaction,
in a 1: 1 surfactant: DNA ratio (Scheme 4.1). The resulting NANs were purified via a Sephadex
NAP-10 column and characterized through DLS and zeta potential measurements (Table 4.1).
Peptide crosslinked AP228 NANs exhibited an average size of 36.4 nm and an average charge of
-37.4 mV, while the PEG crosslinked NANs had an average size and charge of 28.4 nm and -45.3
mV, respectively. The negative charge of the NANs confirms the successful addition of thiolated
DNA to the surface of the nanocapsule. The size and charge of the AP209 loaded NANs was
similar to that of the AP228 loaded NANs (Table 4.1). The NANs did not show large amounts of
aggregation in the DLS measurements, likely due to the repulsion between particles due to the
highly negatively charged surface.

Table 4.1. Characterization of SCMs and NANs.
Average size and charge of the various SCMs and NANs.35
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Cellular update of metallodrug-NANs. After successful synthesis and characterization, it was
important to confirm the cellular uptake of the drug-NANs. This was first investigated using
confocal microscopy. For these studies, a TYE665-labeled DNA was ligated to the surface of PEGcrosslinked metallodrug-NANs, using a 1: 1 ratio of NAN: TYE-665 labeled DNA. The successful
ligation was characterized via a 3% agarose gel. HeLa cells were treated with 1 µM dye-labeled
NANs for 4 hours in OptiMEM and imaged with a Leica SP8 confocal microscope. (Figure 4.6).
The confocal images show the successful uptake of the NANs, as seen by the red signal throughout
the cell.

Figure 4.6. Confocal microscopy images.
Confocal microscopy images of HeLa cells treated with either TYE665-labeled DNA or TYE665-labeled
DNA-functionalized metallodrug-NANs. These images show effective uptake of drug-NANs, without
the use of transfection agents. Scale bars are 20 µm.35
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To better investigate whether the NANs were endocytosed into cells, metallodrug-NANs were
functionalized with fluorescein-labeled DNA, following a typical NAN synthesis and
characterized via DLS and zeta potential measurements. HeLa cells were treated with 1 µM PEGcrosslinked metallodrug-NANs for 4 hours in OptiMEM and stained with Lysotracker Deep Red
for 30 minutes before imaging. The confocal images showed the overlay of the green (fluorescein)
and red (Lysotracker) channels, confirming the endocytosis of the NANs (Figure 4.7).

Figure 4.7. Confocal microscopy images.
Confocal microscopy images of HeLa cells treated with either free
fluorescein DNA, transfected with lipofectamine (B), or with
metallodrug-NANs functionalized with fluorescein DNA (C) AP209
NANs, D) AP228 NANs). The overlay of the red channel and green
channel for both AP209 and AP228 NANs shows colocalization of
NANs in cellular endosomes. Scale bars are 20 µm.35

101

As the metallodrugs contain a gold atom in the structure, ICP-MS analysis was also used to
investigate cellular uptake of metallodrug-NANs by measuring the relative gold amounts in treated
cells. HeLa cells were treated with either 1 µM metallodrug-NANs or 25 nM free AP228 for 4
hours, trypsinized, pelleted, counted, and submitted for analysis. Pellets were stored at -80 °C prior
to analysis. It is important to note that PEG-crosslinked NANs were used in this analysis to prevent
toxicity during treatment. ICP-MS results show that compared to untreated cells, both AP209 and
AP228 NANs increased the amount of gold present in the sample (Figure 4.8). However, the
relative amount of gold present in AP228-NAN treated cells was much higher than that of AP209NAN treated cells, likely due to better incorporation of the smaller, less polar metallodrug into the
hydrophobic core of the NAN.

Figure 4.8. ICP-MS analysis.
ICP-MS analysis of relative amounts of gold in HeLa cells treated with 1 µM AP209 NANs, 1 µM AP228
NANs, or 25 nM free AP228, compared to untreated cells. The relative amount of gold present in AP228
NAN treated cells was significantly higher than the other samples.35
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Another method of evaluating cellular uptake of metallodrug NANs was through scanning electron
microscopy/energy dispersive X-ray spectroscopy (SEM/EDS). SEM is a technique that allows for
the visualization of samples via a focused electron beam. The interaction of the electrons with the
sample results in the production of secondary and backscatter electrons, which are used to generate
an image. In addition, characteristic X-rays are produced due to the electron-sample interaction.
In EDS, these characteristic X-rays are detected and used to determine the elemental composition
of the sample. As each gold(III) metallodrug contains one gold atom, it was hypothesized that
SEM/EDS analysis could be applied to visualize endosomes containing metallodrug-NANs.

As there is a relatively low amount of gold present in the AP228 NAN samples, AuNP NANs were
utilized as a proof of concept to show that the gold signal from endocytosed NANs could be
measured using SEM/EDS. To synthesize AuNP NANs, micelles containing AuNPs were prepared
following a recently published protocol.34 100 µL of 13 nm AuNPs in cyclohexane was added to
a 1.5 mL tube and dried completely with nitrogen. 2 mg of surfactant (5 mM), 1 mL water, and 20
µL hexane were added to the dried AuNPs, sonicated, and stirred overnight in air. As the AuNPs
are capped with tetradecylamine, micelles were formed due to hydrophobic interactions between
the surfactant molecule and the surface ligand. Additionally, the surfactant concentration was kept
below the critical micelle concentration (CMC) to avoid the formation of empty micelles. To form
SCMs, 10 µL of a 25 mg/mL sodium ascorbate solution, 1.25 µL Cu-THPTA, and 0.5 µL diazido
PEG crosslinker were added to 1 mL micelles. The resulting solution was stirred at room
temperature for 4 hours. After crosslinking, SCMs were centrifuged at 15000 rpm for 1 hour.
Supernatant was removed and the pellet was resuspended in 1 mL water. To form NANs, 500 µL
SCMs (approximately 7 nM by gold concentration) and 5 µL DHEMPP was added to 100 µM
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thiolated anchor. The solution was placed in a Rhyonet UV box for 30 minutes and purified via
centrifugation at 15000 rpm for 30 minutes. The supernatant was removed and the pellet was
resuspended in 500 µL water.

For SEM/EDS analysis, HeLa cells were placed in a single well of a 6-well plate containing a
small piece of silicon wafer at 100,000 cells/mL and incubated overnight at 37 °C and 5% CO2.
Cells were then treated with either 1 µM PEG crosslinked AuNP-loaded NANs or 1 µM PEG
crosslinked AP228-loaded NANs in OptiMEM for 4 hours at 37 °C. After incubation, cells were
washed with 1x PBS. As SEM/EDS is performed under vacuum, fixation of cells is important to
avoid distortion of the sample. 2 mL of 4% paraformaldehyde was added to the cells and incubated
for 15 minutes at room temperature. Cells were washed with 1x PBS and allowed to dry
completely. Samples were stored at 4 °C until use. As biological samples are non-conductive, the
high energy electrons of the electron beam can cause damage to the sample due to charge buildup.
Thus, the sample was coated with a conductive layer of carbon prior to imaging.

In SEM, backscatter electrons are used to generate an image. As the production of backscatter
electrons is proportional to atomic number, regions of high atomic number in a sample appear
brighter than regions of low atomic number. The SEM image of HeLa cells treated with AuNP
NANs (Figure 4.9) showed the presence of a bright region in the cell. The EDS analysis of the
region shows a strong gold signal. As the region is greater than 100 nm in diameter, it was
hypothesized that the signal is due to the AuNP NANs trapped in cellular endosomes.
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Figure 4.9. SEM/EDS analysis of HeLa cells treated with AuNP NANs.
A) and B) SEM images of a cell with an area of high intensity (B is a zoom-in of the area in A). C) EDS
analysis of the area showing a strong gold signal.

Similarly, for cells treated with AP228 NANs, the SEM image (Figure 4.10) showed the presence
of a similar high intensity region. As late endosomes are reported to be 600-750 nm in diameter,36,37
the region likely represents an endosome containing AP228 NANs. Additionally, EDS analysis
showed the presence of gold in the region. The lower gold signal in the AP228 NAN treated cells
vs. the AuNP NAN treated cells was expected as the metallodrug only contains one gold atom,
resulting in lower concentrations of gold relative to the AuNP NANs.

Figure 4.10. SEM/EDS analysis of HeLa cells treated with AP228 NANs, showing an area of
concentrated gold in the cell.
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Effect of encapsulation on structure and activity of metallodrugs. After confirming the cellular
uptake of the NANs, it was then of interest to investigate the effect of encapsulation of
metallodrugs into the core of the nanocapsule, as the release of intact Au(III) metallodrug is crucial
to the cytotoxicity of the drug. The characterization of pre- and post-encapsulated metallodrugs
was carried out via a series of UV-vis spectroscopy measurements. For the analysis of free AP228
free metallodrug was first dissolved in DMSO and then added to a 1: 1 mixture of DMSO: PBS.
The analysis of free AP209 was performed in 100% DMSO, to avoid precipitation of the drug.
The characteristic absorbance peak of a gold(III) complex was seen at 260 nm for both
metallodrugs (Figure 4.11).

Figure 4.11. UV-vis analysis of free metallodrug.
The absorbance peak at 260 nm is a characteristic peak of gold(III) complexes.35
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As the gold atom has two bromine ligands, the presence of water in the sample could result in the
exchange of the bromines for a more soluble diaqua species. To investigate this exchange, the UVvis spectra of free metallodrug in 50% DMSO in PBS was monitored over the course of an hour.
The hydrolysis of the metallodrug was visualized over time as the emergence of a peak at 315 nm
(Figure 4.12).

Figure 4.12. UV-vis analysis of free metallodrug over 1 hour in 50% DMSO/PBS.
The absorbance peak that emerges at 315 shows the exchange of the bromine ligands for water.35

The effects of encapsulation and eventual release of the metallodrugs were also investigated using
UV-vis analysis. 2 mM AP228-loaded SCMs in 3% DMSO in PBS showed an absorbance peak at
260 nm, representing the Au(III) complex (Figure 4.13). A large absorbance peak is also seen at
315 nm, showing the hydrolysis of the drug. However, this was expected as the measurements
were taken in 3% DMSO in PBS. The low percentage of DMSO was due to the addition of 10%
fetal bovine serum (FBS) to the sample. As FBS is full of various proteases and nucleases, it was
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expected that the addition of FBS to the sample would result in the degradation of the nanocapsule.
Thus, the release of the drug was monitored at 37 °C for 6 hours. The UV-vis spectra of the SCMs
also showed an absorbance peak at 500 nm, which is hypothesized to represent the closely packed
Au(III) compounds inside the core of the nanocapsule (Figure 4.13). The degradation of peptidecrosslinked SCMs was investigated after the addition of 10% FBS to the solution. The proteases
present in the serum cleaved the peptide crosslinker of the SCM, resulting in release of
encapsulated AP228. Over time, the release of metallodrug was visualized as the decrease in the
absorbance peak at 500 nm (Figure 4.13).

Figure 4.13. UV-vis analysis of AP228-loaded SCMs treated with 10% FBS over 6 hours.
The decrease of the absorbance peak at 500 nm over time corresponds to the release of
metallodrug from the SCM.35
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While it was promising that the release of the drug could be visualized using UV-vis spectroscopy,
it was important to test the overall efficacy of the drug after its release from the NAN. The gold(III)
complexes are thought to interact with and inhibit thioredoxin reductase, leading to severe
oxidative stress and eventual cellular apoptosis.17 Thus, it was expected that the two Au(III)
metallodrugs utilized in this study would also act as thioredoxin reductase inhibitors. To further
investigate the stability and activity of the metallodrugs delivered with the NAN platform, HeLa
cells were incubated with either 17.5 µM AP228-loaded peptide-crosslinked NANs or 0.4375 µM
free AP228 for 4 hours. The concentration of free AP228 added to cells is comparable to the
concentration of drug in the AP228 NAN sample with a 2.5% loading efficiency. After incubation,
cells were washed, trypsinized, pelleted and lysed with cold lysis buffer. The cell lysate was
centrifuged 12,000 rpm for 15 minutes at 4 °C. The supernatant was collected, and the relative
activity of TrxR was analyzed using a Thioredoxin Reductase Activity Colorimetric Assay Kit
(BioVision) (Figure 4.14). Compared to untreated cells, which showed high levels of TrxR
activity (as seen by the increase in absorbance), cells treated with metallodrug-NANs showed
inhibition of TrxR. This inhibition of TrxR activity was comparable to that of a commercially
available inhibitor.
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Figure 4.14. Thioredoxin reductase activity assay.
Untreated HeLa cells (black line) show enzyme activity, visualized by the increase in
absorbance over time. HeLa cells treated with 17.5 µM AP228 NANs (green line) or
.4375 µM free AP228 (purple line) showed loss of thioredoxin reductase activity,
comparable to cells treated with a commercially available inhibitor (blue), or a
combination of drug + inhibitor (red).35

Toxicity of drug-NANs. To more specifically test the effects of the NAN-mediated delivery of
the metallodrug, the toxicity of AP209 and AP228 was investigated in HeLa cells. First, it was
important to investigate the effect of the empty, peptide-crosslinked NAN on cell viability. HeLa
cells were incubated with varying concentrations of peptide-NANs for 24 hours, and a standard
MTS assay was used to determine percent cell viability. There was no decrease in cell viability in
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any concentrations tested, up to 10 µM NAN, meaning that the surfactant of the micelle and the
peptide used as the crosslinker did not cause any toxicity (Figure 4.15).

Figure 4.15. Viability of HeLa cells treated with varying
concentrations of empty peptide-crosslinked NANs.35

It was then of interest to investigate the toxicity of each metallodrug encapsulated in the core of
the NAN. HeLa cells were incubated with either 1 µM free AP209 or AP228, or 0.56 µM, 1 µM,
or 20 µM metallodrug-loaded NANs. At 2.5% loading capacity of the nanocapsules, the
concentrations of NANs used correspond to 15 nM drug, 25 nM drug, and 500 nM drug,
respectively. After 24 hours, a decrease in cell viability was observed between the empty NANtreated cells and the cells treated with 20 µM AP209 or AP228-loaded NANs (Figure 4.16).
Additionally, minimal toxicity was seen from 1 µM free drug when added directly to cell media.
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Figure 4.16. Viability of HeLa cells treated with increasing concentrations of metallodrugNANs.
Cells treated with 500 nM drug/NANs showed a decrease in cell viability compared to cells
treated with 1µM free drug.35

Enhanced cytotoxicity of drug when co-delivered with siRNA targeting Bcl-2. While there
was a decrease in cell viability with lower overall drug concentrations using the NAN platform, a
main interest was to investigate the effect that the co-delivery of siRNA and metallodrug had on
cell viability. As Bcl-2 is a protein involved in the regulation of apoptosis, it was hypothesized that
the combination of Bcl-2 knockdown with the effects of the metallodrugs would result in
significantly lower cell viabilities vs. the delivery of Bcl-2 or metallodrug only.

Thus, drug-loaded NANs were further functionalized with siRNA targeting Bcl-2. The sense
strand of Bcl-2 siRNA was enzymatically ligated to the surface of a peptide substrate crosslinked
metallodrug-NAN. The anti-sense strand of the siRNA duplex was then hybridized to the sense
strand presented on the surface of the NAN (Figure 4.17). The degradation of the peptide-
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crosslinked NAN results in the release of nucleic acid-surfactant conjugates. As shown in chapter
2, the surfactant tail aids in the endosomal escape of the released nucleic acid-surfactant conjugate.
As the anti-sense strand is the active therapeutic component of the siRNA duplex, the
dehybridization of the duplex in the cellular environment allows for the anti-sense strand to engage
target mRNA in the cytosol.

Figure 4.17. Functionalization of NAN with siRNA.

PEG-crosslinked NANs were utilized in the initial investigation of the efficiency of Bcl-2 mRNA
knockdown with the NAN construct to prevent toxicity during analysis. HeLa cells were treated
with 250 nM NANs for 4 hours, washed, trypsinized, and lysed. Total RNA was isolated via a
Qiagen RNeasy Kit. Reverse transcription was performed using iScript Supermix (Bio-Rad),
following the protocol provided by the manufacturer. Real time PCR was performed using
appropriate primers and iTaq SYBR Green Supermix (Bio-Rad). PCR was carried out on a BioRad CFX Connect Real-Time PCR Detection System, and mRNA expression values were
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calculated via analysis tools provided with the instrument. GAPDH mRNA expression levels were
utilized as a control for normalization. Compared to untreated cells, NANs functionalized with
Bcl-2 siRNA achieved approximately 60% knockdown in Bcl-2 mRNA (Figure 4.18).

The knockdown from the NAN construct is comparable to the knockdown seen with commercially
available Bcl-2 siRNA. However, it was necessary to transfect the siRNA control into cells using
Lipofectamine 2000 to see effective mRNA cleavage, while the NANs did not require the addition
of any transfection agents. Additionally, when the siRNA sequence on the surface of the NAN
was altered to be non-targeting, no mRNA cleavage was observed (Figure 4.18), highlighting the
specificity of the siRNA for its target mRNA sequence.

Figure 4.18. Bcl-2 mRNA knockdown.
HeLa cells treated with PEG crosslinked siRNA-functionalized metallodrug-NANs
showed knockdown of Bcl-2 mRNA comparable to that of a commercially available
siRNA control that was transfected into cells. NANs functionalized with non-targeting
siRNA did not show any mRNA knockdown.35
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After confirming the siRNA’s ability to cleave Bcl-2 mRNA intracellularly using the NAN
platform, the PEG crosslinker was changed to a cathepsin B peptide substrate crosslinker, to allow
for both mRNA knockdown and drug release. To investigate cell viability, HeLa cells were treated
with either 15 nM free AP228, 0.56 µM empty peptide-crosslinked NANs, 0.56 µM empty peptidecrosslinked NANs functionalized with Bcl-2, or 0.56 µM AP228-loaded peptide-crosslinked
NANs functionalized with Bcl-2. It is important to note that the loading capacity of the NANs was
previously determined to be 2.5%, meaning 0.56 µM NAN corresponds to 15 nM drug.

Figure 4.19. Viability of HeLa cells after co-delivery of AP228 and
Bcl-2 targeting siRNA.
Compared to free drug and empty NANs functionalized with
siRNA, cells treated with drug-loaded siRNA-NANs showed a
significant decrease in cell viability.35
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After a 24-hour incubation, cells treated with empty peptide-crosslinked NANs and 15 nM free
AP228 showed no decrease in cell viability (Figure 4.19). Empty NANs functionalized with Bcl2 siRNA resulted in a 50% decrease in cell viability. However, as Bcl-2 plays a key role in
regulating cellular apoptosis, it was expected that the downregulation of Bcl-2 would have an
effect on cell viability. Importantly, cells treated with AP228-NANs functionalized with Bcl-2
siRNA exhibited only about 30% cell viability, which is a significant decrease compared to those
treated with Bcl-2 functionalized NANs only (Figure 4.19).

In order to comprehensively illustrate the synergistic effects of the co-delivery of siRNA and the
gold(III) metallodrugs, dose response studies were carried out and the IC50 of each system was
determined. The IC50 of AP228 NANs functionalized with Bcl-2 siRNA was determined to be 11.3
nM, which is significantly lower than that of empty NANs functionalized with Bcl-2 siRNA (644
nM) and free AP228 (760 nM) (Figure 4.20). This shows that the co-delivery of metallodrug with
a therapeutic nucleic acid targeting Bcl-2 does result in enhanced drug efficacy.
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Figure 4.20. Dose response curves.
IC50 curves for free AP228, empty NANs functionalized with siRNA, and AP228 NANs
functionalized with siRNA.35

Summary
In summary, it has been shown that encapsulation of the Au(III) metallodrugs into the hydrophobic
core of the NAN results in an enhancement in drug efficacy, likely due to the better solubilization
of the drug and the intracellular localization resulting from the endocytosis of the NAN. It has also
been shown that the drug maintained activity post-encapsulation, resulting in the effective decrease
in cell viability. Finally, the studies show that cell viability is significantly decreased with the codelivery of the metallodrug alongside siRNA targeting an anti-apoptotic gene. Overall, the NAN
shows promise as an effective delivery vehicle for the co-delivery of a therapeutic nucleic acid
with a small molecule drug, with improved cellular delivery and sustained toxicity at overall lower
drug concentrations.
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Chapter 5
Aptamer-functionalized NANs for targeted gene regulation

Introduction
Targeted therapeutics have become increasingly important as a lack of targeting can result in low
therapeutic efficacy and off-target effects. Active targeting of therapeutics involves the use of
ligands that are capable of selectively binding a cell surface receptor.1

Aptamers are single stranded nucleic acid molecules with unique defined structures that are
generated via an in vitro selection (SELEX)2,3 to bind a target with high affinity, with Kd values
ranging from picomolar to nanomolar.4 SELEX, or systematic evolution of ligands by exponential
enrichment, begins with a large library of oligonucleotides consisting of random sequences flanked
by constant 3’ and 5’ regions (Figure 5.1). The library typically consists of approximately 1015
different sequences.5 The oligonucleotides are exposed to a purified target ligand, and those that
do not bind are removed. Bound sequences are then amplified by polymerase chain reaction (PCR),
and exposed to the target ligand again, under new conditions. The process continues until a small
number of sequences that bind the target ligand with high affinity remain. In contrast, cell basedSELEX utilizes whole, live cells as the target. This allows for the isolation of aptamers using
targets in their native conformation and under more physiologically relevant conditions.6,7

120

Figure 5.1. General overview of an in vitro selection.
A large library of random sequences is introduced to the target of interest, and any sequences that
do not bind are removed. The sequences that do bind the target are amplified by PCR, and the library
is again introduced to the target, under new selection conditions. The cycle continues until only a
small number of sequences that bind the target with high affinity remain.

Aptamers can act as therapeutics on their own. Macugen, also known as pegaptanib, was approved
by the FDA in 2004 for the treatment of age-related macular degeneration (AMD).8 AMDassociated vision loss is typically linked to vascular permeability and neovascularization under the
retina of the eye.9 Macugen is an RNA aptamer that binds vascular endothelial growth factor
(VEGF). The signaling pathway of VEGF is critical to the formation of new blood vessels.10 By
binding VEGF, Macugen blocks this signaling pathway, which prevents blood vessel growth.33
This strong and selective binding of the target results in a therapeutic effect, not just a targeting
effect. Aptamers can also be used as targeting ligands for cell-specific drug delivery. Successful
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targeting has been shown with aptamers conjugated to siRNA,11,12 small molecule drugs,13,14
proteins,15 liposomes,16,17,18 and nanoparticles.19,20,21

There are a number of benefits to using aptamers as therapeutic ligands, as they have a
straightforward and low-cost synthesis and a lack of immunogenicity compared to antibodies.7
Aptamers have a long shelf-life and can be easily chemically modified to enhance stability,4 and
have been shown to retain binding properties, even when immobilized on a surface.4,22
Additionally, aptamers are highly specific for their targets, as they can distinguish between
morphologically similar cells.23

Previous chapters have shown that the nucleic acid nanocapsule (NAN) construct is a versatile
platform for the delivery of therapeutic oligonucleotides and the controlled release of encapsulated
small molecule drugs. In this chapter, it was of interest to functionalize the NAN with an aptamer
to allow for targeted, cell-specific drug delivery and gene knockdown. The NAN surface was
functionalized with an anti-Annexin A2 aptamer, ACE4, isolated via a cell-based in vitro selection
in 2014.24
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Figure 5.2. Chemical structure of 2’-fluoro modified
pyrimidine RNA.

The selection library consisted of RNA chemically modified with 2’-fluoro modified pyrimidines
(2’F-Py RNA) (Figure 5.2), allowing for increased resistance to nuclease degradation, while
retaining a lack of immunogenicity.25,26 However, the original selection performed aimed to isolate
an aptamer against Endothelin type B receptor (ETBR), a transmembrane protein receptor involved
in vascular disease.27 After 15 selection cycles with CHO-K1 cells that were transfected to express
ETBR, seven individual sequences exhibited high affinity binding to the target cells vs. a scrambled
sequence.24 Of these, ACE4 (Figure 5.3) was chosen as it exhibited the highest binding affinity
for the target on human MCF-7 cells, however, ACE4 could not discriminate between cell lines
that expressed ETBR vs. those that lacked ETBR.24 Further experiments using MCF-7 cells
determined that the target of ACE4 was Annexin A2, a phospholipid binding protein located on
the surface of endothelial cells.24 Annexin A2 is upregulated in various cancers,28 and has been
shown to play a major role in tumor cell invasion, adhesion, and metastasis.29,30,31,32

123

Figure 5.3. Predicted structure of ACE4.24

In collaboration with the lab of Dr. Frédéric Ducongé (Commissariat à l’Energie Atomique et aux
Energies Alternatives (CEA)), we obtained the Annexin A2 aptamer. In this chapter, the ability of
the aptamer to bias the cellular uptake of the NAN construct was investigated via confocal
microscopy. Additionally, NANs will be dually functionalized with the GATA-3 specific
DNAzyme along with the active aptamer sequence. Our hypothesis is that the functionalization of
the NAN with the Annexin A2 aptamer will allow for targeted, cell-specific mRNA knockdown.
Achieving specific mRNA knockdown is important as it allows for the silencing of relevant genes
in a disease, while having a limited effect on healthy cells.
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Preparation of SCMs and NANs. First, SCMs are prepared by dissolving 1.0 mg of surfactant in
water. SCMs are crosslinked with the diazido PEG crosslinker via copper(I) catalyzed click
chemistry between the azide group of the crosslinker and the alkyne of the surfactant. After
crosslinking, SCMs were purified via size exclusion chromatography and characterized by
dynamic light scattering (DLS) and zeta potential measurements (Figure 5.4). The SCMs were
approximately 23 nm in diameter with an average charge of 48 mV.

Table 5.1. DNA and RNA sequences.
Blue represents monophosphorylation site to allow for T4 DNA ligase recognition.

125

To make aptamer-functionalized NANs, PR anchor was added to PEG SCMs in a 1:1 ratio via a
UV-mediated thiol-yne reaction. The PR anchor was dually modified with a 3’ thiol and a 5’
monophosphate (Table 5.1). The 3’ thiol allowed for the attachment of the anchor to the surface
of the NAN, while the 5’ monophosphate was important for the enzymatic ligation to the 3’
hydroxyl of the aptamer. NANs were purified via size exclusion chromatography and the
successful attachment of anchor to the surface was characterized by DLS and zeta potential
measurements (Figure 5.4). NANs exhibited an average size of 38 nm and an average surface
charge of -43 mV.

Figure 5.4. DLS and zeta potential measurements of PEG crosslinked SCMs and NANs.
Full width at half maximum for the size distribution was calculated to be 14.5 for SCMs
and 15.6 for NANs.
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Ligation of Annexin A2 aptamer. As the aptamer consists of a long (119 nucleotide), highly
folded sequence, it was first important to evaluate the ligation efficiency of the aptamer sequence
to the anchor. As the aptamer relies on its 5’ end for target binding, modification of the aptamer
for ligation was avoided. Thus, the anchor utilized in the ligation (PR anchor) was dually modified
with a 3’ thiol, to allow for attachment to the NAN surface, and a 5’ monophosphate for the ligation
to the 3’ hydroxyl of the aptamer.

Figure 5.5. Ligation of ACE4 to PR anchor.
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For the in-solution ligation of aptamer to anchor (Table 5.1), 1 µM of ACE4 was added to 5 µM
PR anchor and 5 µM PR bridge in water. The solution was heated at 85 °C for 5 minutes and
cooled to room temperature prior to ligation to allow for hybridization of the bridge to the aptamer
and anchor (Figure 5.5). The ligation was done at 37 °C overnight, and the crude ligation product
was run on an 8% denaturing PAGE gel (Figure 5.6). The gel shows the successful ligation of the
aptamer to the anchor, visualized by a shift in the band. However, there was still unligated ACE4
present after ligation. Additionally, higher molecular weight bands in the gel were visualized.
These likely represent dimers due to the interaction of the thiols present on the anchor sequence or
hybridization products due to interactions between the sequences.

Figure 5.6. 8% PAGE gel of the crude in-solution ligation product.
After ligation, the aptamer-anchor product was visualized, along with unligated
aptamer.
After confirming the successful ligation of the aptamer sequence to the monophosphorylated
anchor in-solution, the aptamer was ligated to the NAN (Figure 5.7). 1 µM NANs were added to
5 µM ACE4 or ACE4scram and 10 µM PR bridge, heated to 85 °C, and cooled back to room
temperature prior to ligation. The ligation was run overnight at 37 °C. Unligated aptamer was
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removed via size exclusion chromatography and the aptamer-NANs were characterized via DLS.
ACE4 NANs had an average size of 127 nm, while ACE4scram NANs were approximately 84 nm
(Figure 5.8).

Figure 5.7. Ligation of aptamer (ACE4 or ACE4scram) to the surface of
the NAN.

Figure 5.8. Average size of ACE4-NANs and ACE4scram-NANs.
Full width at half maximum for the size distribution was calculated to be 30.7 for the ACE4
functionalized-NANs and 23.2 for ACE4scram functionalized-NANs.
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Targeted cellular uptake of aptamer-NANs. The ability of the active aptamer (ACE4) to
selectively bind Annexin A2 was investigated via confocal microscopy. In order to visualize the
aptamer, a biotinylated DNA sequence was first hybridized to the aptamer (Figure 5.9).
Streptavidin-phycoerythrin (streptavidin-PE), which consists of streptavidin conjugated to a red
pigmented protein, was then added. The streptavidin bound the biotin present on the aptamer,
resulting in fluorophore labeling of the aptamer (Figure 5.9).

Figure 5.9. Fluorophore labeling of aptamer for confocal microscopy.
A biotinylated DNA sequence (biotin spacer) is first hybridized to the aptamer.
Streptavidin-PE, which consists of streptavidin conjugated to a fluorescent
protein, then binds the biotin, resulting in fluorophore labeling.

Hybridization of the biotin spacer was done by adding 1 µM of biotin spacer to 1 µM aptamer in
RPMI media. RPMI media was used in the hybridization and cell incubation as it was the media
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used in the in vitro selection of ACE4.24 The resulting solution was heated to 85 °C for 5 minutes,
and slowly cooled to room temperature. 75 nM hybridized product and Lysotracker Deep Red
were added to MCF-7 cells and incubated for 30 minutes at 37 °C in RPMI. The Lysotracker
selectively stains the cellular endosomes and lysosomes. Cells were washed with 1X PBS to
remove any unbound aptamer. Cells were incubated with Hoechst 33342 for 5 minutes and washed
with 1X PBS. 1 µL of streptavidin-PE in RMPI was added and incubated for 5 minutes. Cells were
washed with 1X PBS, and imaged at various time points to investigate the binding and cellular
uptake of the aptamer.

Confocal images show that the active ACE4 sequence was bound to the surface of cells at 10
minutes. Additionally, the aptamer was endocytosed at 60 minutes, visualized by the colocalization
of the aptamer (green channel) and endosomes (red channel). (Figure 5.10). Alternatively, when
the sequence was scrambled (ACE4scram), no fluorescence was visualized (Figure 5.10). These
results mean that the active aptamer sequence was successful in binding the target on the surface
of MCF-7 cells, while the scrambled sequence did not bind the cells and was washed away prior
to imaging.
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Figure 5.10. Confocal microscopy images of MCF-7 cells treated with active aptamer (ACE4) or
scrambled aptamer (ACE4scram).
At 10 minutes, the active aptamer is visualized around the surface of the cells. By 60 minutes, the
colocalization of aptamer (green channel) with lysotracker (red channel) shows the successful
endocytosis of the aptamer. Alternatively, limited fluorescence is visualized in MCF-7 cells treated with
the scrambled aptamer sequence. This is likely due to the removal of unbound aptamer in the washing
steps. Scale bars are 20 µm.
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It was then of interest to investigate the ability of the aptamer to bias the binding and cellular
uptake of the NAN construct. Biotin spacer was hybridized to the NAN surface by adding 250 nM
biotinylated DNA to 250 nM PEG crosslinked NANs. The solution was heated at 85 °C for 5
minutes, and slowly cooled to room temperature. 75 nM hybridized NANs and Lysotracker Deep
Red were added to MCF-7 cells and incubated for 30 minutes at 37 °C in RPMI. Unbound NANs
were removed by washing the cells with 1X PBS. Cell nuclei were stained with Hoechst 33342 for
5 minutes. Cells were washed with 1X PBS, and 5 µL of streptavidin-PE in RMPI was added and
incubated for 5 minutes. Cells were washed with 1X PBS and RPMI was replaced. Images were
then taken at various time points.

Figure 5.11. Confocal microscopy images of MCF-7 cells treated with aptamer-NANs.
After treatment with the active aptamer-NAN (ACE4-NAN), cells show endocytosis of NANs by 60
minutes. Limited fluorescence is visualized in cells treated with scrambled aptamer-NANs (ACE4scramNAN), as unbound NANs were removed prior to imaging. Scale bars are 20 µm.
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The confocal microscopy images show enhanced uptake into the MCF-7 cells with the active
Annexin A2 aptamer (ACE4)-functionalized NANs compared to the cells treated with scrambled
aptamer (ACE4scram)-functionalized NANs (Figure 5.11). After 60 minutes, the active aptamerfunctionalized NANs are colocalized in cellular endosomes. Additionally, there is limited
fluorescence from cells treated with scrambled aptamer NANs, likely due to the removal of the
unbound particles during the washing step. These results show active ACE4 is able to bias the
cellular uptake of the NANs compared to the scrambled aptamer sequence.

Dually-functionalized NANs for cell-specific mRNA knockdown. After confirming the
evidence of biased uptake, it was of interest to investigate whether the aptamer-NANs could
achieve cell-specific mRNA cleavage. For these studies, NANs were dually functionalized with
the GATA-3 specific DNAzyme and ACE4. It was first important to investigate NANs
functionalized with varying ratios of DNAzyme and aptamer in order to achieve maximal targeting
and knockdown, as the substitution of a large number of aptamers on the NAN surface for
DNAzyme could potentially sacrifice targeting to achieve therapeutic efficacy.
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Table 5.2. DNA and RNA sequences for dually-functionalized NANs.
Blue represents monophosphorylation to allow for T4 DNA ligase recognition.

Ester crosslinked NANs were first prepared with varying ratios of PR anchor and AH anchor
(Table 5.2). The two separate anchors allow for control of the ratio of DNAzyme to aptamer after
ligation. The PR anchor consists of a 3’ thiol for the thiol-yne reaction to the surface of the SCM
and a 5’ monophosphate which allows for the ligation of the 3’ hydroxyl of the aptamer.
Alternatively, the AH anchor consists of a 5’ thiol utilized in the thiol-yne reaction to the SCM
surface. The 3’ hydroxyl of the AH anchor is ligated to the 5’ monophosphate of the GATA-3
DNAzyme. Three different ratios were prepared: 1 PR anchor : 1 AH anchor, 10 PR anchor : 1
AH anchor, and 1 PR anchor : 10 AH anchor (Figure 5.12).

After synthesis, NANs were purified and characterized by DLS and zeta potential measurements
(Figure 5.13). All NANs were approximately 10 nm in diameter with average surface charges of
around -30 mV.
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Figure 5.12. NANs functionalized with varying ratios of PR anchor and AH anchor.

Figure 5.13. Characterization of dual-anchor NANs.
Full width at half maximum for the size distribution was calculated to be 6.0 for 1 PR
anchor : 1 AH anchor NANs, 9.2 for 10 PR anchor : 1 AH anchor NANs, and 11.7 for 1
PR anchor : 10 AH anchor NANs.
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NANs were then dually functionalized with the GATA-3 specific DNAzyme and active aptamer
sequence via two separate enzymatic ligations. To first investigate whether the NANs could be
successfully functionalized with both the DNAzyme and the aptamer, 1 PR anchor : 1 AH anchor
NANs were used in the initial ligations. First, the DNAzyme was ligated to the surface of the NAN.
For the ligation, 10 µM NANs were added to 20 µM DNAzyme, 20 µM DNAzyme bridge, and 20
µM PR bridge (for a final ratio of 1 NAN : 2 DNAzyme : 4 bridge). Both bridges were added to
the solution to prevent the ligation of DNAzyme to the PR anchor. The solution was heated at 70
°C and cooled to room temperature prior to ligation to allow for hybridization. As the ligation is a
DNA-DNA ligation, it was placed at 25 °C for 2 hours. Ligase was heat inactivated at 70 °C for
10 minutes, and the resulting DNAzyme-NANs were purified via size exclusion chromatography
using a NAP10 column. To ligate the aptamer, 1 µM DNAzyme-NANs were added to 5 µM
aptamer (ACE4 or ACE4scram) and 10 µM PR bridge (for a final ligation ratio of 1 NAN : 5
aptamer : 10 bridge). To allow for hybridization, the resulting solution was heated at 85 °C and
cooled to room temperature prior to ligation. As it was a hybrid DNA-RNA ligation, it was
performed at 37 °C overnight. Ligase was heat inactivated at 70 °C and the dually-functionalized
NANs were purified via size exclusion chromatography using a NAP5 column. After each ligation
and purification, NANs were characterized by DLS. After the ligation of the DNAzyme, there was
a shift in the size to approximately 56 nm (Figure 5.14). Additionally, after the aptamer was ligated
to the DNAzyme-NANs, the NANs increased in average size to roughly 105 nm (for the active
aptamer sequence) and 84 nm (for the scrambled aptamer sequence). The size shift after each
ligation is attributed to the successful ligation of each sequence on the surface.
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Figure 5.14. Average size of NANs functionalized with DNAzyme only, and of NANs functionalized
with both DNAzyme and aptamer.
The large range in sizes after the ligation of the aptamer to the DNAzyme-NAN surface can be
attributed to the nature of the aptamer, and the potential for it to fold and unfold on the timescale of
the DLS measurements, creating a larger size distribution. Full width at half maximum for the size
distribution was calculated to be 24.3 for NANs + DNAzyme, 30.7 for NANs + DNAzyme + ACE4,
and 23.2 for NANs + DNAzyme + ACE4scram.
Future directions: cell-specific mRNA cleavage. The ability of the DNAzyme-aptamer-NAN
to achieve biased cell uptake and mRNA knockdown will be further investigated using two
separate cell lines, MCF-7 and PC-3. As MCF-7 cells express Annexin A2, it is hypothesized that
cells treated with the DNAzyme-aptamer-NANs should show a significant reduction in the
expression of GATA-3 mRNA relative to untreated cells. Alternatively, PC-3 cells do not express
Annexin A2,24 and therefore should show limited uptake of the NAN construct. The limited uptake
of DNAzyme-NANs should not significantly affect the relative expression of GATA-3 mRNA in
the treated PC-3 cells. The dually-functionalized NAN constructs with varying ratios of DNAzyme
to aptamer will be investigated in order to achieve highly efficient, targeted knockdown.
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Preliminary studies on biased mRNA knockdown in MCF-7 and PC-3 cells have been done in an
attempt to optimize incubation conditions. Both cell lines were treated with 250 nM duallyfunctionalized NANs consisting of equal DNAzyme and aptamer concentrations for both 10
minutes and 15 minutes, in either DMEM or RPMI media. After incubation with the NANs, cells
were washed and incubated an additional 4 hours. After a brief initial attempt at this experiment,
there was no difference in mRNA expression levels between the cell lines, regardless of media and
incubation time. Thus, it is important to further optimize both the treatment conditions and the
ratio of DNAzyme to aptamer on the NAN surface. Additionally, biased uptake between MCF-7
and PC-3 cells will be evaluated via confocal microscopy. For these studies, a confocal chamber
was designed by Joseph Luciani (University of Connecticut Innovative Partnership Building, Proof
of Concept Center) to allow for simultaneous treatment of the two different cell lines (Figure
5.15). The design allows for separate culturing of MCF-7 and PC-3 cells, while the modification
to the middle wall allows for the media and NAN treatment to be distributed evenly over the two
cell lines.

Figure 5.15. Design of a modified confocal chamber.
The modified middle wall allows for NAN treatment
to be evenly distributed over the separate MCF-7 and
PC-3 cell lines.
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Using this new confocal chamber, we will assess the affinity of the aptamer-functionalized NAN
for each cell line during co-culture. This experiment aims to determine the ability of the aptamerNAN to undergo enhanced cellular uptake in cell lines that express Annexin A2 compared to those
that lack Annexin A2 on the surface, with the eventual goal of achieving cell-specific mRNA
knockdown.

Summary
In this chapter, it was shown through confocal microscopy that the functionalization of the NAN
surface with an aptamer results in biased cell uptake due to the targeting of specific cell receptors.
Additionally, NANs were functionalized with both a DNAzyme and aptamer and characterized
with DLS measurements. The dually-functionalized NANs will be evaluated in their ability to
achieve biased mRNA cleavage in cell lines that express Annexin A2, which is important as it
would allow for gene silencing in diseased cells vs. healthy cells. The mRNA knockdown in
unintended cells could be detrimental to the health of an organism, so this targeted knockdown
would be exciting. Additionally, targeted mRNA knockdown is an underexplored approach in the
field of gene regulation due to the lack of cell targeting techniques.
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Chapter 6
Summary and Outlook
In summary, this work has focused on the design and characterization of a novel, enzymeresponsive nucleic acid nanocapsule (NAN). Throughout the chapters of this thesis, we have
investigated the ability of the NAN construct to achieve intracellular delivery of therapeutic
nucleic acids and small molecule drugs.

Chapter 1 describes the initial design and characterization of the novel nucleic acid nanocapsule
(NAN) construct, which undergo active cellular uptake through endocytosis. As the NAN does not
require the addition of cationic transfection agents to achieve cellular uptake, they exhibit limited
toxicity.

In chapter 2, the surface of the NAN was further functionalized with a GATA-3 specific
DNAzyme. The dense coating of nucleic acids on the surface of the NAN resulted in enhanced
stability of the chemically unmodified DNAzyme, and the stepwise assembly of the NAN and the
ligation of the DNAzyme to the surface were shown to be very efficient. Additionally, studies with
a mock lipid bilayer system showed that the surfactant tail chemically tethered to the DNAzyme
after nanocapsule degradation aids in the endosomal escape of the nucleic acid. Importantly, the
DNAzyme-functionalized NANs were shown to achieve efficient GATA-3 mRNA cleavage in
MCF-7 cells, indicating the enhanced stability of the DNAzyme on the NAN surface. Overall, the
results highlight the promising potential of the NAN platform for the intracellular delivery of a
therapeutic nucleic acid.
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Chapter 3 expands the in vitro studies to human primary immune cells, which are traditionally
difficult to transfect. Additionally, the activity of DNAzyme-NANs was also investigated through
in vivo studies. To enhance biochemical specificity, DNAzyme NANs were prepared with a
peptide substrate crosslinker specific for MMP9. DNAzyme-NANs showed a significant
improvement in allergic airway disease severity, measured by a reduction of airway eosinophilia
in a house dust mite-associated allergic airway disease mouse model. DNAzyme-NANs showed
successful cellular uptake by primary blood mononuclear cells (PBMCs), highlighting uptake by
human immune cells. Specifically, CD4+ T cells showed a 23% uptake of DNAzyme-NANs. As
CD4+ T cells express GATA-3, they are the main target of the DNAzyme-NANs. The cleavage of
GATA-3 mRNA in isolated CD4+ T cells was also investigated. While preliminary studies show
a minor reduction of mRNA after a 12-hour treatment, it is of interest to evaluate mRNA
expression levels after longer incubation times. However, due to the low expression of GATA-3
in PBMCs isolated from healthy patients, the ability of the DNAzyme-NAN to achieve significant
GATA-3 mRNA reduction was also investigated in Jurkat cells. As the inflammatory response to
an allergen in asthma leads to the upregulation of GATA-3, production of T cells, and release of
cytokines, it would also be interesting to investigate the mRNA knockdown in CD4+ T cells
isolated from patients with asthma, compared with those isolated from healthy patients.
Additionally, it is of interest to maximize the cellular uptake of DNAzyme-NANs by the CD4+ T
cells. This can be achieved by the dual functionalization of NANs with the GATA-3 DNAzyme
and a CD4-targeting aptamer.

Chapter 4 describes the co-delivery of a small molecule drug and a therapeutic nucleic acid using
the NAN platform. Au(III) metallodrugs were encapsulated in the hydrophobic core of the NAN,
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while the surface of the NAN was functionalized with siRNA targeting an anti-apoptotic gene. The
co-delivery resulted in significantly enhanced therapeutic efficacy of the drug at lower overall
concentrations. Based on the encouraging results presented in Chapter 4 using the NAN to codeliver a small molecule drug and a therapeutic nucleic acid, future experiments could include the
encapsulation of a common corticosteroid drug for the treatment of asthma in the DNAzyme-NAN.

Finally, chapter 5 discussed the functionalization of the NAN surface with an anti-Annexin A2
aptamer for targeted delivery. The ability of an active aptamer sequence to bias the cellular uptake
of the NANs, compared to NANs functionalized with a scrambled aptamer sequence, was
investigated through confocal microscopy. Additionally, NANs were designed to be duallyfunctionalized with both the active aptamer sequence and the previously described GATA-3
DNAzyme. It is of interest to further investigate the ability of the dually-functionalized aptamerNANs to achieve biased mRNA knockdown, which would allow for gene regulation in diseased
cells, while having limited off-target effects.

Overall, the NAN platform serves as a promising vehicle for the intracellular delivery of
therapeutic nucleic acids. The enzyme-responsive crosslinker allows for degradation of the NAN
in response to specific stimuli, and the resulting surfactant-nucleic acid conjugates achieve
enhanced endosomal escape. Additionally, the modular design allows for co-delivery of an
encapsulated small molecule drug and a therapeutic nucleic acid ligand. This opens up new
avenues for future drug-oligonucleotide combinations for the treatment of numerous diseases.
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Appendix
Surface crosslinked micelle (SCM) synthesis: PEG or ester crosslinked
1.9 mg of surfactant (.005 mmol) was dissolved in 483.2 µL Millipore water. Solution was stirred
at room temperature for 30 minutes. 10 µL of a 25 mg/mL sodium ascorbate solution (.00125
mmol), 5 L of a 25 mM THPTA-Cu complex (.000125 mmol), and 1.8 µL diazido ester crosslinker
or diazido PEG crosslinker (.006 mmol) were added to a total volume of 500 µL. Mixture was
stirred at room temperature for 3.5 hours. The product was purified by a Sephadex G-25 NAP-10
column (GE Healthcare), and the fractions containing surface crosslinked micelles (SCMs) were
characterized through dynamic light scattering (DLS) and zeta potential on a Malvern Zetasizer
Nano ZS90.
Surface crosslinked micelle (SCM) synthesis: peptide crosslinked
1.0 mg of surfactant (.005 mmol) was dissolved in 211.5 µL Millipore water. 25 µL of a 50 mM
peptide stock (in DMSO) (.0025 mmol) and 20 µM 2-hydroxy-4-(2-hydroxyethoxy)-2methylpropiophenone (DHEMPP) was added, and the solution was stirred in a Rhyonet reactor for
30 minutes. Unpurified SCMs were characterized via DLS and zeta potential measurements on a
Malvern Zetasizer Nano ZS90.
Nucleic acid nanocapsule (NAN) synthesis
A solution containing 100 µM SCMs, 200 µM thiolated DNA, and 20 µM of 2-hydroxy-4- (2hydroxyethoxy)-2-methylpropiophenone (DHEMPP) in a total volume of 500 µL was placed in a
Rhyonet reactor for 30 minutes. The resulting product was purified by a Sephadex G-25 NAP- 10
column, and the fractions were characterized by DLS and zeta potential measurements on a
Malvern Zetasizer Nano ZS90.
Ligation of GATA-3 DNAzyme
20 µM GATA-3 DNAzyme and 40 µM DNAzyme bridge were added to 10 µM NANs
functionalized with DNA anchor. Water was added to a total volume of 300 µL. The solution was
heated at 70 °C for 10 minutes and cooled to room temperature. 5 mM ATP, 15 µL of 1 U/µL T4
DNA Ligase (Invitrogen), and 1x ligase buffer were mixed. Water was added to a total volume of
300 µL. Placed on a 25 °C heat block for 2 hours. Ligase was heat inactivated at 65 °C for 10
minutes. Product was washed through a Sephadex G-25 NAP-10 column to purify unligated
DNAzyme from DNz-NANs. Fractions were then analyzed by DLS.
Cell viability assay (MTS)
Cells (HeLa or MCF-7) were cultured in a 96-well plate for 24 hours at 10,000-15,000 cells/mL.
Appropriate concentrations of each treatment was added and incubated for 22 hours. 20 μL of
CellTiter 96 Aqueous One Solution (Promega) was added to each well, and incubated for an
additional 2 hours. Absorbance at 490 nm was measured with a BioTek Cytation5 microplate
reader.
Full width at half maximum (FWHM) calculations
FWHM
values
were
calculated
in
Excel
using
=MAX(IF(B1:B69>=MAX(B1:B69)/2,A1:A69),MIN(A1:A69))146

the

following

formula:

MIN(IF(B1:B69>=MAX(B1:B69)/2,A1:A69),MAX(A1:A69)), where A1-A69 were the x-axis
values (size in nm), and B1-B69 were y-axis values (% intensity).
ANOVA analysis
Statistical significance calculations (ANOVA: Single Factor) were carried out in Excel via the
Data Analysis add-on, where p values < 0.05 represented statistical significance.
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